

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/IMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the  
IPC reform  
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUIDB, and IFICDB  
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
  
NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:23:37 ON 30 JAN 2006

=> file polymer medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'APOLLIT' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (c) 2006 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 09:24:02 ON 30 JAN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (c) 2006 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 09:24:02 ON 30 JAN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 09:24:02 ON 30 JAN 2006  
Compendex Compilation and Indexing (C) 2006  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'NTIS' ENTERED AT 09:24:02 ON 30 JAN 2006  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2006)

FILE 'PASCAL' ENTERED AT 09:24:02 ON 30 JAN 2006  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 09:24:02 ON 30 JAN 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 09:24:02 ON 30 JAN 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:24:02 ON 30 JAN 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 09:24:02 ON 30 JAN 2006  
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:24:02 ON 30 JAN 2006

FILE 'BIOSIS' ENTERED AT 09:24:02 ON 30 JAN 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 09:24:02 ON 30 JAN 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s urinary(a)tract(a)infect?

15 FILES SEARCHED...

L1 118295 URINARY(A) TRACT(A) INFECT?

=> s l1 and treat?

17 FILES SEARCHED...

L2 42971 L1 AND TREAT?

=> s l2 and D-mannose

22 FILES SEARCHED...

L3 142 L2 AND D-MANNOSE

=> s l3 and (crataeva or willow or pollen)

L4 5 L3 AND (CRATAEVA OR WILLOW OR POLLEN)

=> dis l4 1-5 bib abs

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:612489 CAPLUS

DN 141:117126

TI Method and composition for maintaining urinary tract health in the face of infections

IN Oneal, Joseph; White, Gary

PA USA

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI	US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

L4 ANSWER 2 OF 5 USPATFULL on STN

AN 2005:10558 USPATFULL

TI Multi-phase, multi-compartment capsular delivery apparatus and methods for using same

IN Miller, Fred H., Tampa, FL, UNITED STATES

PI US 2005008690 A1 20050113

AI US 2004-804576 A1 20040319 (10)

RLI Continuation-in-part of Ser. No. WO 2003-US10816, filed on 9 Apr 2003, PENDING

PRAI US 2002-371448P 20020410 (60)

DT Utility

FS APPLICATION

LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007

CLMN Number of Claims: 118  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 6126

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 5 USPATFULL on STN  
AN 2004:190686 USPATFULL  
TI Method and composition for maintaining urinary tract health in the face of infections  
IN Oneal, Joseph, Irving, TX, UNITED STATES  
White, Gary, Irving, TX, UNITED STATES  
PI US 2004147459 A1 20040729  
AI US 2003-691423 A1 20031022 (10)  
PRAI US 2002-420696P 20021023 (60)  
DT Utility  
FS APPLICATION  
LREP CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 295

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The sugar mannose has been used to maintain urinary tract health in the face of E. coli infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 5 USPATFULL on STN  
AN 87:56793 USPATFULL  
TI Method for the treatment of adult respiratory distress syndrome  
IN Raffin, Thomas A., Palo Alto, CA, United States  
Stevens, John H., Palo Alto, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University, Stanford, CA, United States (U.S. corporation)  
PI US 4686100 19870811  
AI US 1985-718918 19850402 (6)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Foelak, Morton; Assistant Examiner: Draper, Garnette D.  
LREP Ciotti & Murashige  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1,8  
DRWN No Drawings

LN.CNT 489

AB A method for treating adult respiratory distress syndrome (ARDS) and sepsis in a patient in need thereof which comprises administering to said patient an antibody to complement component C5a or the des Arg derivative thereof in an amount effective to treat ARDS and sepsis.

L4 ANSWER 5 OF 5 WPINDEX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2004-570523 [55] WPINDEX

DNC C2004-208289

TI Use of D-mannose for maintenance of urinary tract health in the face of infection e.g. E. Coli infection.

DC B03 B04

IN ONEAL, J; WHITE, G

PA (ONEA-I) ONEAL J; (WHIT-I) WHITE G

CYC 1

PI US 2004147459 A1 20040729 (200455)\* 6

ADT US 2004147459 A1 Provisional US 2002-420696P 20021023, US 2003-691423 20031022

PRAI US 2002-420696P 20021023; US 2003-691423 20031022

AN 2004-570523 [55] WPINDEX

AB US2004147459 A UPAB: 20040826

NOVELTY - Maintenance of urinary tract health in the face of infection involves administering a dosage of 1 - 2 teaspoons of D-mannose three times a day with meals for 1 - 2 weeks or until the symptoms subside.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition comprising a therapeutic dosage of D-mannose and a therapeutic dosage of at least one of an extract of Crataeva nurvala, willow bark or pollen extract simultaneously with D-mannose.

ACTIVITY - Uropathic; Antimicrobial.

MECHANISM OF ACTION - E. coli urethral epithelial cell attachment inhibitor.

USE - For maintaining urinary tract health in the face of infection; in combination with a capsule containing herbs that affect the urinary tract; and for dealing with a urinary tract infection (all claimed). The urinary tract infection include E. coli infection.

ADVANTAGE - The use of D-mannose in the maintenance of urinary tract health in the face of infection and in the treatment of urinary tract infection preferentially provides attachment of E. coli fimbriae to the administered D-mannose present in the urine, rather than attachment to D-mannose in the epithelial cells of the urinary tract. This results in the E. coli bacteria surrounded by the molecules of D-mannose and promotes their natural elimination by mechanical and not pharmacological action. The few remaining bacteria can then be better handled by the body's natural defenses, the white blood cells. Mannose can not be broken down in the body, and thus is safe for diabetics, pregnant women and the elderly, and is virtually free from the risk of overdose. The method does not involve the use of antibiotics and hence avoids the side effects and resistant strain development associated with them. The administration regimen provides a quantity of mannose sufficient to remove a majority of E/ coli in the urinary tract, while improving the ease of use and compliance. The dosages are effective in doctor-run trials.

Dwg.0/3

=> s l3 and (cratavin or salicin)

L5 7 L3 AND (CRATAVIN OR SALICIN)

=> dis l5 1-7 bib abs

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:612489 CAPLUS

DN 141:117126

TI Method and composition for maintaining urinary tract health in the face of  
infections  
IN Oneal, Joseph; White, Gary  
PA USA  
SO U.S. Pat. Appl. Publ., 6 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI	US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

L5 ANSWER 2 OF 7 USPATFULL on STN  
AN 2005:10558 USPATFULL  
TI Multi-phase, multi-compartment capsular delivery apparatus and methods for using same  
IN Miller, Fred H., Tampa, FL, UNITED STATES  
PI US 2005008690 A1 20050113  
AI US 2004-804576 A1 20040319 (10)  
RLI Continuation-in-part of Ser. No. WO 2003-US10816, filed on 9 Apr 2003, PENDING  
PRAI US 2002-371448P 20020410 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007  
CLMN Number of Claims: 118  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 6126

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 7 USPATFULL on STN  
AN 2004:190686 USPATFULL  
TI Method and composition for maintaining urinary tract health in the face of infections  
IN Oneal, Joseph, Irving, TX, UNITED STATES  
White, Gary, Irving, TX, UNITED STATES  
PI US 2004147459 A1 20040729  
AI US 2003-691423 A1 20031022 (10)  
PRAI US 2002-420696P 20021023 (60)  
DT Utility  
FS APPLICATION  
LREP CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380

CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 295

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The sugar mannose has been used to maintain urinary tract health in the face of E. coli infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophalaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 7 USPATFULL on STN  
AN 2004:82309 USPATFULL  
TI Combination of probiotics  
IN Mayra-Makinen, Annika, Helsinki, FINLAND  
Suomalainen, Tarja, Helsinki, FINLAND  
Vaarala, Outi, Helsinki, FINLAND  
PI US 2004062758 A1 20040401  
AI US 2003-470151 A1 20031022 (10)  
WO 2002-FI35 20020117  
PRAI FI 2001-157 20010125  
DT Utility  
FS APPLICATION  
LREP Nixon & Vanderhye, 8th Floor, 1100 North Glebe Road, Arlington, VA,  
22201-4714

CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 827

AB The invention relates to a probiotic combination comprising different combinations of lactobacilli, propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.

L5 ANSWER 5 OF 7 USPATFULL on STN  
AN 81:67074 USPATFULL  
TI Allylic methyl-hydroxylated novobiocins  
IN Sebek, Oldrich K., Kalamazoo, MI, United States  
Dolak, Lester A., Cooper Township Kalamazoo County, MI, United States  
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)  
PI US 4304855 19811208  
AI US 1977-793784 19770505 (5)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Hruskoci, Peter A.  
LREP Stein, Bruce  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 680

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a fermentation process for producing allylic methyl-hydroxylated novobiocin and derivatives thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 7 USPATFULL on STN  
AN 79:18080 USPATFULL

TI Allylic methyl-hydroxylated novobiocins  
IN Sebek, Oldrich K., Kalamazoo, MI, United States  
Dolak, Lester A., Cooper Township, Kalamazoo County, MI, United States  
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)  
PI US 4148992 19790410  
AI US 1978-878115 19780215 (5)  
RLI Division of Ser. No. US 1977-793784, filed on 5 May 1977, now Defensive  
Publication No.  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Brown, Johnnie R.  
LREP Stein, Bruce  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a fermentation process for producing  
allylic methyl-hydroxylated novobiocin and derivatives thereof. These  
hydroxy novobiocins (II) are useful as antibiotics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 7 USPATFULL on STN  
AN 78:66969 USPATFULL  
TI Allylic methyl-hydroxylated novobiocins  
IN Sebek, Oldrich K., Kalamazoo, MI, United States  
Dolak, Lester A., Kalamazoo, MI, United States  
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)  
PI US 4128563 19781205  
AI US 1978-878114 19780215 (5)  
RLI Division of Ser. No. US 1977-793784, filed on 5 May 1977, now Defensive  
Publication No.  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Trousof, Natalie; Assistant Examiner: Fan, Jane T.  
LREP Stein, Bruce  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 648

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a fermentation process for producing  
allylic methyl-hydroxylated novobiocin and derivatives thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 13 and (capsule or powder)

22 FILES SEARCHED...

L6 86 L3 AND (CAPSULE OR POWDER)

=> s 13 and lupeol

L7 1 L3 AND LUPEOL

=> dis 17 bib abs

L7 ANSWER 1 OF 1 USPATFULL on STN  
AN 2004:190686 USPATFULL  
TI Method and composition for maintaining urinary tract health in the face  
of infections  
IN Oneal, Joseph, Irving, TX, UNITED STATES  
White, Gary, Irving, TX, UNITED STATES  
PI US 2004147459 A1 20040729  
AI US 2003-691423 A1 20031022 (10)  
PRAI US 2002-420696P 20021023 (60)  
DT Utility  
FS APPLICATION  
LREP CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380



CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 295

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The sugar mannose has been used to maintain urinary tract health in the face of E. coli infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophalaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis 16 1-86 bib abs

L6 ANSWER 1 OF 86 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:612489 CAPLUS

DN 141:117126

TI Method and composition for maintaining urinary tract health in the face of infections

IN Oneal, Joseph; White, Gary

PA USA

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI	US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

L6 ANSWER 2 OF 86 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:543349 CAPLUS

DN 141:94307

TI Compositions comprising plant extracts and sugar for use in inhibiting bacterial proliferation

IN Clayton, Paul; Conn, Helen

PA Forum Bioscience Holdings Limited, UK

SO Brit. UK Pat. Appl., 17 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2396811	A1	20040707	GB 2003-29467	20031219
	WO 2004056380	A2	20040708	WO 2003-GB5578	20031219
	WO 2004056380	A3	20040916		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2002-30042 A 20021223

AB Claimed is a composition comprising an extract from a plant that is a member of Ericaceae, Rosaceae, Pinaceae, or Vitaceae family and at least one sugar that is not metabolized or is only partly metabolized by the body. The sugar is preferably a monosaccharide, such as L-arabinose, L-fucose, D-mannose, L-rhamnose, L-xylose, lyxose or galactose. A preferred composition comprises an extract of cranberry with D-mannose. These comps. may be used to treat bacterial infection caused by E. coli, particularly urinary tract infections. Comps. comprising an anthocyanidin or a proanthocyanidin and at least one sugar that is not metabolized or is only partly metabolized by the human or animal body are also described.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 86 USPATFULL on STN

AN 2006:15872 USPATFULL

TI Albumin fusion proteins

IN Haseltine, William A., Washington, DC, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

PI US 2006014254 A1 20060119

AI US 2005-175690 A1 20050707 (11)

RLI Continuation of Ser. No. WO 2004-US1369, filed on 20 Jan 2004, PENDING

PRAI US 2003-441305P 20030122 (60)

US 2003-453201P 20030311 (60)

US 2003-467222P 20030502 (60)

US 2003-472816P 20030523 (60)

US 2003-476267P 20030606 (60)

US 2003-505172P 20030924 (60)

US 2003-506746P 20030930 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 17653

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L6 ANSWER 4 OF 86 USPATFULL on STN

AN 2005:330573 USPATFULL

TI Carbohydrate encapsulated nanoparticle based affinity mass spectrometry

IN Lin, Chun-Cheng, Fongyuan City, TAIWAN, PROVINCE OF CHINA

Chen, Yu-Ju, Lugang Township, TAIWAN, PROVINCE OF CHINA

PA Academia Sinica, Office of Public Affairs (Technology Transfer), Taipei, TAIWAN, PROVINCE OF CHINA (non-U.S. corporation)

PI US 2005287552 A1 20051229

AI US 2005-91649 A1 20050328 (11)

RLI Continuation-in-part of Ser. No. US 2004-782076, filed on 19 Feb 2004, PENDING

PRAI US 2003-448716P 20030219 (60)

DT Utility

FS APPLICATION

LREP Jason R. Bond, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 2470

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods and compositions for carbohydrate encapsulated nanoparticle based mass spectrometry. For example, the present invention provides methods of screening samples for carbohydrate binding molecules, methods of characterizing carbohydrate binding epitopes in target molecules, and MALDI matrix compositions comprising carbohydrate encapsulated nanoparticles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 86 USPATFULL on STN

AN 2005:305894 USPATFULL

TI Albumin fusion proteins

IN Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

PA Human Genome Sciences, Inc. (U.S. corporation)  
Delta Biotechnology Limited (U.S. corporation)

PI US 2005266533 A1 20051201

AI US 2005-78914 A1 20050314 (11)

RLI Continuation of Ser. No. US 2001-832501, filed on 12 Apr 2001, ABANDONED

PRAI US 2000-256931P 20001221 (60)

US 2000-199384P 20000425 (60)

US 2000-229358P 20000412 (60)

DT Utility

FS APPLICATION

LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US

CLMN Number of Claims: 21

ECL Exemplary Claim: 1-60

DRWN 20 Drawing Page(s)

LN.CNT 13941

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 86 USPATFULL on STN

AN 2005:305893 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

PA Human Genome Sciences, Inc. (U.S. corporation)  
Principia Pharmaceutical Corporation (U.S. corporation)

PI US 2005266532 A1 20051201

AI US 2005-78663 A1 20050314 (11)

RLI Continuation of Ser. No. US 2001-833117, filed on 12 Apr 2001, ABANDONED

PRAI US 2000-229358P 20000412 (60)  
US 2000-199384P 20000425 (60)  
US 2000-256931P 20001221 (60)  
DT Utility  
FS APPLICATION  
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK  
AVENUE, NW, WASHINGTON, DC, 20001-4413, US  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1-59  
DRWN 20 Drawing Page(s)  
LN.CNT 12894

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 86 USPATFULL on STN  
AN 2005:280980 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PA Human Genome Sciences, Inc. (U.S. corporation)  
PI US 2005244931 A1 20051103  
AI US 2004-967457 A1 20041019 (10)  
RLI Division of Ser. No. US 2001-833041, filed on 12 Apr 2001, PENDING  
DT Utility  
FS APPLICATION  
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK  
AVENUE, NW, WASHINGTON, DC, 20001-4413, US  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1-33  
DRWN 20 Drawing Page(s)  
LN.CNT 16289

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 86 USPATFULL on STN  
AN 2005:274503 USPATFULL  
TI 67 human secreted proteins  
IN Ruben, Steven M., Olney, MD, UNITED STATES  
Ferrie, Ann M., Painted Post, NY, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Florence, Kimberly, Rockville, MD, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Florence, Charles, Rockville, MD, UNITED STATES  
Young, Paul E., Gaithersburg, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES

Endress, Gregory A., Florence, MA, UNITED STATES  
Feng, Ping, Gaithersburg, MD, UNITED STATES  
Janat, Fouad, Westerly, RI, UNITED STATES  
Birse, Charles, North Potomac, MD, UNITED STATES

PI US 2005239059 A1 20051027  
AI US 2001-949925 A1 20010912 (9)  
RLI Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999,  
PENDING Continuation-in-part of Ser. No. US 1999-363044, filed on 29 Jul  
1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US1621, filed  
on 27 Jan 1999, PENDING  
PRAI US 2000-232150P 20000912 (60)  
US 1998-73170P 19980130 (60)  
US 1998-73167P 19980130 (60)  
US 1998-73165P 19980130 (60)  
US 1998-73164P 19980130 (60)  
US 1998-73162P 19980130 (60)  
US 1998-73161P 19980130 (60)  
US 1998-73160P 19980130 (60)  
US 1998-73159P 19980130 (60)  
US 1998-73170P 19980130 (60)  
US 1998-73167P 19980130 (60)  
US 1998-73165P 19980130 (60)  
US 1998-73164P 19980130 (60)  
US 1998-73162P 19980130 (60)  
US 1998-73161P 19980130 (60)  
US 1998-73160P 19980130 (60)  
US 1998-73159P 19980130 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY  
GROVE ROAD, ROCKVILLE, MD, 20850, US

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 21427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and  
isolated nucleic acids containing the coding regions of the genes  
encoding such proteins. Also provided are vectors, host cells,  
antibodies, and recombinant methods for producing human secreted  
proteins. The invention further relates to diagnostic and therapeutic  
methods useful for diagnosing and treating diseases,  
disorders, and/or conditions related to these novel human secreted  
proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 86 USPATFULL on STN

AN 2005:268651 USPATFULL

TI Antibacterial compounds and methods for treating gram positive  
bacterial infections

IN McCafferty, Dewey G., Plymouth Meeting, PA, UNITED STATES

PA The Trustees of the University of Pennsylvania, Philadelphia, PA, UNITED  
STATES (U.S. corporation)

PI US 2005233971 A1 20051020

AI US 2003-516012 A1 20030602 (10)

WO 2003-US17215 20030602  
20041129 PCT 371 date

PRAI US 2003-385038P 20020531 (60)

DT Utility

FS APPLICATION

LREP NATH & ASSOCIATES, 1030 15th STREET, NW, 6TH FLOOR, WASHINGTON, DC,  
20005, US

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 1960

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present inventive subject matter relates to novel antibacterial

compounds that are capable of inhibiting bacterial multiplication and killing living bacteria. The present inventive subject matter further relates to methods for treating Gram positive bacterial infections using the inventive compounds.

##STR1##

##STR2##

R.sub.1

R.sub.2

- |   |  |                |
|---|--|----------------|
| 1 | $\alpha$ -D-Mannosyl-(1 $\rightarrow$ 2)- $\alpha$ - | D-mannose      |
|   | NH.sub.3.sup.+                                       |                |
| 2 | H  | NH.sub.3.sup.+ |
| 3 | $\alpha$ -D-Mannosyl-(1 $\rightarrow$ 2)- $\alpha$ - | D-mannose      |
|   | HNC(NH)NH.sub.3.sup.+                                |                |
| 4 | $\alpha$ -D-Mannosyl-(1 $\rightarrow$ 2)- $\alpha$ - | D-mannose      |
|   | HN.sup.+(CH.sub.2).sub.2CH(CH.sub.3).sub.2           |                |
| 5 | $\alpha$ -D-Mannosyl-(1 $\rightarrow$ 2)- $\alpha$ - | D-mannose NHAc |
| 6 | $\alpha$ -D-Mannosyl-(1 $\rightarrow$ 2)- $\alpha$ - | D-mannose      |
|   | NH.sub.3.sup.+ (Lactone hydrolyzed)                  |                |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 86 USPATFULL on STN  
AN 2005:267622 USPATFULL  
TI Recombinant DNA, plasmid, transformed microorganism and vaccine protein for prevention and therapy of urinary tract infection  
IN Pyo, Suhk-Neung, Seoul, KOREA, REPUBLIC OF  
Lee, Yong-Hwa, Seoul, KOREA, REPUBLIC OF  
PI US 2005232938 A1 20051020  
AI US 2004-877670 A1 20040625 (10)  
PRAI KR 20040419  
DT Utility  
FS APPLICATION  
LREP JORDAN AND HAMBURG LLP, 122 EAST 42ND STREET, SUITE 4000, NEW YORK, NY, 10168, US  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 1374

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a novel vaccine against Escherichia coli (E. coli) responsible for urinary tract infections. The vaccine is a recombinant chimeric protein which is prepared by linking by genetic recombination a gene encoding an antigenic determinant of uropathogenic E. coli to a CTXA2B gene encoding nontoxic A2 and B subunits of Vibrio cholerae cholera toxin (CTX) or a LTXA2B gene encoding nontoxic A2 and B subunits of E. coli heat-labile enterotoxin, wherein a translation product of the CTXA2B or LTXA2B gene serves as an immunogenic adjuvant stimulating mucosal immune responses, expressing the resulting recombinant gene in E. coli, and isolating and purifying an expressed recombinant fusion protein. The recombinant chimeric protein is useful as an oral vaccine with mild side effects and excellent vaccination efficiency against uropathogenic E. coli. Thus, the chimeric vaccine protein can remarkably reduce recurrence of urinary tract infections, prevent occurrence of antibiotic-resistant bacteria, and replace the conventional chemotherapy for urinary tract infections. Also, the chimeric vaccine protein has other advantages of being capable of being produced and commercialized in a short period with relatively low costs, and being easily modified by replacing its genetic constituents with other genes to provide various vaccines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 86 USPATFULL on STN  
 AN 2005:248575 USPATFULL  
 TI 70 human secreted proteins  
 IN Ruben, Steven M., Brookeville, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Fischer, Carrie L., Burke, VA, UNITED STATES  
 Soppet, Daniel R., Centreville, VA, UNITED STATES  
 Carter, Kenneth C., North Potomac, MD, UNITED STATES  
 Bednarik, Daniel P., Columbia, MD, UNITED STATES  
 Endress, Gregory A., Florence, MA, UNITED STATES  
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 Feng, Ping, Germantown, MD, UNITED STATES  
 Young, Paul E., Gaithersburg, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Painted Post, NY, UNITED STATES  
 Duan, D. Roxanne, Bethesda, MD, UNITED STATES  
 Hu, Jing-Shan, Mountain View, CA, UNITED STATES  
 Florence, Kimberly A., Rockville, MD, UNITED STATES  
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Brewer, Laurie A., St. Paul, MN, UNITED STATES  
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
 PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)  
 PI US 2005215775 A1 20050929  
 AI US 2004-979111 A1 20041102 (10)  
 RLI Division of Ser. No. US 2000-621011, filed on 20 Jul 2000, GRANTED, Pat. No. US 6878687 Continuation of Ser. No. US 1998-148545, filed on 4 Sep 1998, GRANTED, Pat. No. US 6590075  
 PRAI WO 1998-US4482 19980306  
 US 1997-40162P 19970307 (60)  
 US 1997-40333P 19970307 (60)  
 US 1997-38621P 19970307 (60)  
 US 1997-40161P 19970307 (60)  
 US 1997-40626P 19970307 (60)  
 US 1997-40336P 19970307 (60)  
 US 1997-40163P 19970307 (60)  
 US 1997-47615P 19970523 (60)  
 US 1997-47600P 19970523 (60)  
 US 1997-47597P 19970523 (60)  
 US 1997-47502P 19970523 (60)  
 US 1997-47633P 19970523 (60)  
 US 1997-47583P 19970523 (60)  
 US 1997-47617P 19970523 (60)  
 US 1997-47618P 19970523 (60)  
 US 1997-47503P 19970523 (60)  
 US 1997-47592P 19970523 (60)  
 US 1997-47581P 19970523 (60)  
 US 1997-47584P 19970523 (60)  
 US 1997-47500P 19970523 (60)  
 US 1997-47587P 19970523 (60)  
 US 1997-47492P 19970523 (60)  
 US 1997-47598P 19970523 (60)  
 US 1997-47613P 19970523 (60)  
 US 1997-47582P 19970523 (60)  
 US 1997-47596P 19970523 (60)  
 US 1997-47612P 19970523 (60)  
 US 1997-47632P 19970523 (60)  
 US 1997-47601P 19970523 (60)  
 US 1997-43580P 19970411 (60)  
 US 1997-43568P 19970411 (60)  
 US 1997-43314P 19970411 (60)  
 US 1997-43569P 19970411 (60)  
 US 1997-43311P 19970411 (60)  
 US 1997-43671P 19970411 (60)  
 US 1997-43674P 19970411 (60)  
 US 1997-43669P 19970411 (60)

US	1997-43312P	19970411	(60)
US	1997-43313P	19970411	(60)
US	1997-43672P	19970411	(60)
US	1997-43315P	19970411	(60)
US	1997-48974P	19970606	(60)
US	1997-56886P	19970822	(60)
US	1997-56877P	19970822	(60)
US	1997-56889P	19970822	(60)
US	1997-56893P	19970822	(60)
US	1997-56630P	19970822	(60)
US	1997-56878P	19970822	(60)
US	1997-56662P	19970822	(60)
US	1997-56872P	19970822	(60)
US	1997-56882P	19970822	(60)
US	1997-56637P	19970822	(60)
US	1997-56903P	19970822	(60)
US	1997-56888P	19970822	(60)
US	1997-56879P	19970822	(60)
US	1997-56880P	19970822	(60)
US	1997-56894P	19970822	(60)
US	1997-56911P	19970822	(60)
US	1997-56636P	19970822	(60)
US	1997-56874P	19970822	(60)
US	1997-56910P	19970822	(60)
US	1997-56864P	19970822	(60)
US	1997-56631P	19970822	(60)
US	1997-56845P	19970822	(60)
US	1997-56892P	19970822	(60)
US	1997-47595P	19970523	(60)
US	1997-57761P	19970905	(60)
US	1997-47599P	19970523	(60)
US	1997-47588P	19970523	(60)
US	1997-47585P	19970523	(60)
US	1997-47586P	19970523	(60)
US	1997-47590P	19970523	(60)
US	1997-47594P	19970523	(60)
US	1997-47589P	19970523	(60)
US	1997-47593P	19970523	(60)
US	1997-47614P	19970523	(60)
US	1997-43578P	19970411	(60)
US	1997-43576P	19970411	(60)
US	1997-47501P	19970523	(60)
US	1997-43670P	19970411	(60)
US	1997-56632P	19970822	(60)
US	1997-56664P	19970822	(60)
US	1997-56876P	19970822	(60)
US	1997-56881P	19970822	(60)
US	1997-56909P	19970822	(60)
US	1997-56875P	19970822	(60)
US	1997-56862P	19970822	(60)
US	1997-56887P	19970822	(60)
US	1997-56908P	19970822	(60)
US	1997-48964P	19970606	(60)
US	1997-57650P	19970905	(60)
US	1997-56884P	19970822	(60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 14367

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic



methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 86 USPATFULL on STN  
AN 2005:236070 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)  
PI US 6946134 B1 20050920  
AI US 2001-833111 20010412 (9)  
PRAI US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Hope A.  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Figure(s); 20 Drawing Page(s)  
LN.CNT 23429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 86 USPATFULL on STN  
AN 2005:226559 USPATFULL  
TI Method of administering FimH protein as a vaccine for urinary tract infections  
IN Langermann, Solomon, Baltimore, MD, UNITED STATES  
Ballou, W. Ripley JR., Silver Springs, MD, UNITED STATES  
PA MedImmune, Inc. (U.S. corporation)  
PI US 2005196408 A1 20050908  
AI US 2005-110609 A1 20050419 (11)  
RLI Continuation of Ser. No. US 2002-306897, filed on 27 Nov 2002, ABANDONED  
Continuation of Ser. No. US 2000-724397, filed on 28 Nov 2000, ABANDONED  
PRAI US 2000-226146P 20000818 (60)  
DT Utility  
FS APPLICATION  
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US  
CLMN Number of Claims: 209  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Page(s)  
LN.CNT 2733

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of stimulating an immune response in a primate utilizing compositions comprising bacterial adhesin proteins and/or immunogenic fragments thereof. The compositions are useful for the prevention and treatment of bacterial induced diseases involving bacterial adherence to a target cell, such as diseases of the urinary tract. More specifically, the invention relates to the vaccination of primates, preferably humans, with protein complexes, such as a purified FimH polypeptides, a purified FimC-FimH (FimCH) polypeptide complex, or immunogenic fragments thereof, to

stimulate protective immunity in the recipient against infection by pathogenic bacteria, including all types of Enterobacteriaceae, preferably E. Coli to produce specific immunoglobulin molecules in the serum and urine or mucosal secretions of the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 86 USPATFULL on STN  
AN 2005:214989 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
Ballance, David J., Berwyn, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES  
PI US 2005186664 A1 20050825  
AI US 2004-775204 A1 20040211 (10)  
RLI Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING  
PRAI US 2001-341811P 20011221 (60)  
US 2002-350358P 20020124 (60)  
US 2002-351360P 20020128 (60)  
US 2002-359370P 20020226 (60)  
US 2002-360000P 20020228 (60)  
US 2002-367500P 20020327 (60)  
US 2002-370227P 20020408 (60)  
US 2002-378950P 20020510 (60)  
US 2002-382617P 20020524 (60)  
US 2002-383123P 20020528 (60)  
US 2002-385708P 20020605 (60)  
US 2002-394625P 20020710 (60)  
US 2002-398008P 20020724 (60)  
US 2002-402131P 20020809 (60)  
US 2002-402708P 20020813 (60)  
US 2002-411355P 20020918 (60)  
US 2002-411426P 20020918 (60)  
US 2002-414984P 20021002 (60)  
US 2002-417611P 20021011 (60)  
US 2002-420246P 20021023 (60)  
US 2002-423623P 20021105 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY  
GROVE ROAD, ROCKVILLE, MD, 20850, US  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1  
DRWN 23 Drawing Page(s)  
LN.CNT 25129

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 86 USPATFULL on STN  
AN 2005:151328 USPATFULL  
TI Carbohydrate encapsulated nanoparticles  
IN Lin, Chun-Cheng, Fung-Yuan City, TAIWAN, PROVINCE OF CHINA  
Chen, Chia-Chu, Taipei, TAIWAN, PROVINCE OF CHINA  
Wu, Yi-Chun, Taipei, TAIWAN, PROVINCE OF CHINA  
PA Academia Sinica, Taipei, TAIWAN, PROVINCE OF CHINA (non-U.S.  
corporation)  
National Taiwan University, Taipei, TAIWAN, PROVINCE OF CHINA (non-U.S.

corporation)  
National Taiwan Normal University, Taipei, TAIWAN, PROVINCE OF CHINA  
(non-U.S. corporation)

PI US 2005130240 A1 20050616  
AI US 2004-782076 A1 20040219 (10)  
PRAI US 2003-448716P 20030219 (60)  
DT Utility  
FS APPLICATION  
LREP MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA,  
94105, US  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Page(s)  
LN.CNT 2061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides carbohydrate encapsulated nanoparticles.  
In particular, the present invention provides metallic nanoparticles  
(e.g. gold nanoparticles) that are encapsulated in biologically  
important carbohydrate molecules, such as sugars, sugar derivatives,  
P-blood group antigens and analogues thereof. The present invention also  
provides methods of employing these carbohydrate encapsulated  
nanoparticles in diagnostic and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 86 USPATFULL on STN  
AN 2005:137948 USPATFULL  
TI Enzymes  
IN Chawla, Narinder K., Union City, CA, UNITED STATES  
Lee, Soo Yuen, Daly City, CA, UNITED STATES  
Ring, Huijun Z., Los Altos, CA, UNITED STATES  
Lee, Ernestine A., Castro Valley, CA, UNITED STATES  
Forsythe, Ian J., Redwood City, CA, UNITED STATES  
Khare, Reena, Saratoga, CA, UNITED STATES  
Tran, Uyen K., San Jose, CA, UNITED STATES  
Kable, Amy E., San Francisco, CA, UNITED STATES  
Richardson, Thomas W., Redwood City, CA, UNITED STATES  
Emerling, Brooke M., Palo Alto, CA, UNITED STATES  
Lindquist, Erika A., Alameda, CA, UNITED STATES  
Baughn, Mariah R., San Leandro, CA, UNITED STATES  
Hafalia, April J.A., Santa Clara, CA, UNITED STATES  
Jin, Pei, Palo Alto, CA, UNITED STATES  
Swarnakar, Anita, San Francisco, CA, UNITED STATES  
Li, Joana X., San Francisco, CA, UNITED STATES  
Marquis, Joseph P., San Jose, CA, UNITED STATES  
Gorvad, Ann E., Livermore, CA, UNITED STATES  
Sprague, William W., Sacramento, CA, UNITED STATES  
Becha, Shanya D., Castro Valley, CA, UNITED STATES  
Elliott, Vicki S., San Jose, CA, UNITED STATES

PI US 2005118594 A1 20050602  
AI US 2003-498788 A1 20021212 (10)  
WO 2002-US40161 20021212  
PRAI US 2003-340357P 20011214 (60)  
US 2003-342962P 20011220 (60)  
US 2003-343558P 20011221 (60)  
US 2003-351107P 20020122 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007,  
US  
CLMN Number of Claims: 59  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 16691

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various embodiments of the invention provide human enzymes (ENZM) and  
polynucleotides which identify and encode-ENZM. Embodiments of the  
invention also provide expression vectors, host cells, antibodies,  
agonists, and antagonists. Other embodiments provide methods for

diagnosing, treating, or preventing disorders associated with aberrant expression of ENZM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 86 USPATFULL on STN  
AN 2005:117724 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PA Human Genome Sciences, Inc. (U.S. corporation)  
PI US 2005100991 A1 20050512  
AI US 2004-932104 A1 20040902 (10)  
RLI Division of Ser. No. US 2001-833118, filed on 12 Apr 2001, PENDING  
DT Utility  
FS APPLICATION  
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK  
AVENUE, NW, WASHINGTON, DC, 20001-4413, US  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 20 Drawing Page(s)  
LN.CNT 15444

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 86 USPATFULL on STN  
AN 2005:89368 USPATFULL  
TI Protein HMAAD57  
IN Ruben, Steven M., Brookeville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Komatsoulis, George, Silver Spring, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)  
PI US 6878687 B1 20050412  
AI US 2000-621011 20000720 (9)  
RLI Continuation of Ser. No. US 1998-148545, filed on 4 Sep 1998, Pat. No. US 6590075 Continuation-in-part of Ser. No. WO 1998-US4482, filed on 6 Mar 1998, PENDING  
PRAI US 1997-57761P 19970905 (60)  
US 1997-57650P 19970905 (60)  
US 1997-56886P 19970822 (60)  
US 1997-56877P 19970822 (60)  
US 1997-56889P 19970822 (60)  
US 1997-56893P 19970822 (60)  
US 1997-56630P 19970822 (60)  
US 1997-56878P 19970822 (60)  
US 1997-56662P 19970822 (60)  
US 1997-56872P 19970822 (60)  
US 1997-56882P 19970822 (60)  
US 1997-56637P 19970822 (60)  
US 1997-56903P 19970822 (60)  
US 1997-56888P 19970822 (60)  
US 1997-56879P 19970822 (60)  
US 1997-56880P 19970822 (60)  
US 1997-56894P 19970822 (60)  
US 1997-56911P 19970822 (60)  
US 1997-56636P 19970822 (60)

US 1997-56874P	19970822 (60)
US 1997-56910P	19970822 (60)
US 1997-56864P	19970822 (60)
US 1997-56631P	19970822 (60)
US 1997-56845P	19970822 (60)
US 1997-56892P	19970822 (60)
US 1997-56632P	19970822 (60)
US 1997-56664P	19970822 (60)
US 1997-56876P	19970822 (60)
US 1997-56881P	19970822 (60)
US 1997-56909P	19970822 (60)
US 1997-56875P	19970822 (60)
US 1997-56862P	19970822 (60)
US 1997-56887P	19970822 (60)
US 1997-56908P	19970822 (60)
US 1997-56884P	19970822 (60)
US 1997-48974P	19970606 (60)
US 1997-48964P	19970606 (60)
US 1997-47615P	19970523 (60)
US 1997-47600P	19970523 (60)
US 1997-47597P	19970523 (60)
US 1997-47502P	19970523 (60)
US 1997-47633P	19970523 (60)
US 1997-47583P	19970523 (60)
US 1997-47617P	19970523 (60)
US 1997-47618P	19970523 (60)
US 1997-47583P	19970523 (60)
US 1997-47592P	19970523 (60)
US 1997-47581P	19970523 (60)
US 1997-47584P	19970523 (60)
US 1997-47500P	19970523 (60)
US 1997-47587P	19970523 (60)
US 1997-47492P	19970523 (60)
US 1997-47598P	19970523 (60)
US 1997-47613P	19970523 (60)
US 1997-47582P	19970523 (60)
US 1997-47596P	19970523 (60)
US 1997-47612P	19970523 (60)
US 1997-47632P	19970523 (60)
US 1997-47601P	19970523 (60)
US 1997-47595P	19970523 (60)
US 1997-47599P	19970523 (60)
US 1997-47588P	19970523 (60)
US 1997-47585P	19970523 (60)
US 1997-47586P	19970523 (60)
US 1997-47590P	19970523 (60)
US 1997-47594P	19970523 (60)
US 1997-47589P	19970523 (60)
US 1997-47593P	19970523 (60)
US 1997-47614P	19970523 (60)
US 1997-47501P	19970523 (60)
US 1997-43580P	19970411 (60)
US 1997-43568P	19970411 (60)
US 1997-43314P	19970411 (60)
US 1997-43569P	19970411 (60)
US 1997-43311P	19970411 (60)
US 1997-43671P	19970411 (60)
US 1997-43674P	19970411 (60)
US 1997-43669P	19970411 (60)
US 1997-43312P	19970411 (60)
US 1997-43313P	19970411 (60)
US 1997-43672P	19970411 (60)
US 1997-43315P	19970411 (60)
US 1997-43578P	19970411 (60)
US 1997-43576P	19970411 (60)
US 1997-43670P	19970411 (60)
US 1997-40162P	19970307 (60)
US 1997-40333P	19970307 (60)
US 1997-38621P	19970307 (60)

US 1997-40161P 19970307 (60)  
US 1997-40626P 19970307 (60)  
US 1997-40334P 19970307 (60)  
US 1997-40336P 19970307 (60)  
US 1997-40163P 19970307 (60)

DT Utility  
FS GRANTED

EXNAM Primary Examiner: Weber, Jon P.; Assistant Examiner: Kam, Chih-Min

LREP Human Genome Sciences, Inc.

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 13992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 86 USPATFULL on STN

AN 2005:77535 USPATFULL

TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria

IN Hultgren, Scott, Ballwin, MO, United States

Kuehn, Meta, Berkeley, CA, United States

Xu, Zheng, Blue Bell, PA, United States

Ogg, Derek, Uppsala, SWEDEN

Harris, Mark, Uppsala, SWEDEN

Lepisto, Matti, Lund, SWEDEN

Jones, Charles Hal, Saint Louis, MO, United States

Kihlberg, Jan, Dalby, SWEDEN

PA SIGA Pharmaceuticals, Inc., New York, NY, United States (U.S. corporation)

Washington University, St. Louis, MO, United States (U.S. corporation)

PI US 6872542 B1 20050329

AI US 2001-799584 20010307 (9)

RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Swartz, Rodney P

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 35 Drawing Figure(s); 25 Drawing Page(s)

LN.CNT 5301

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 86 USPATFULL on STN

AN 2005:63530 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PI US 2005054570 A1 20050310  
AI US 2004-775180 A1 20040211 (10)  
RLI Continuation of Ser. No. WO 2002-US40892, filed on 23 Dec 2002, PENDING  
PRAI US 2001-341811P 20011221 (60)  
US 2002-360000P 20020228 (60)  
US 2002-378950P 20020510 (60)  
US 2002-398008P 20020724 (60)  
US 2002-411355P 20020918 (60)  
US 2002-414984P 20021002 (60)  
US 2002-417611P 20021011 (60)  
US 2002-420246P 20021023 (60)  
US 2002-423623P 20021105 (60)  
US 2002-350358P 20020124 (60)  
US 2002-359370P 20020226 (60)  
US 2002-367500P 20020327 (60)  
US 2002-402131P 20020809 (60)  
US 2002-402708P 20020813 (60)  
US 2002-370227P 20020408 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY  
GROVE ROAD, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 20949

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 86 USPATFULL on STN  
AN 2005:63014 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PA Human Genome Sciences, Inc. (U.S. corporation)  
PI US 2005054051 A1 20050310  
AI US 2004-922142 A1 20040820 (10)  
RLI Division of Ser. No. US 2001-832929, filed on 12 Apr 2001, PENDING  
DT Utility  
FS APPLICATION  
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW,  
WASHINGTON, DC, 20005  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 20 Drawing Page(s)  
LN.CNT 17526

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion

proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 86 USPATFULL on STN  
AN 2005:57259 USPATFULL  
TI EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution  
IN Kiener, Peter A., Doylestown, PA, UNITED STATES  
Kinch, Michael S., Laytonsville, MD, UNITED STATES  
Langermann, Solomon, Baltimore, MD, UNITED STATES  
PI US 2005049176 A1 20050303  
AI US 2004-823259 A1 20040412 (10)  
PRAI US 2003-462009P 20030411 (60)  
DT Utility  
FS APPLICATION  
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3294

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hypoproliferative cell disorder, especially those disorders relating to the destruction, shedding, or inadequate proliferation of epithelial and/or endothelial cells, particularly interstitial cystitis (IC) and lesions associated with inflammatory bowel disease (IBD). The methods of the invention comprise the administration of an effective amount of one or more agents that are antagonists of EphA2. In certain embodiments, the EphA2 antagonistic agent of the invention decreases EphA2-endogenous ligand binding, upregulates EphA2 gene expression and/or translation, increases EphA2 protein stability or protein accumulation, decreases EphA2 cytoplasmic tail phosphorylation, promotes EphA2 kinase activity (other than autophosphorylation or ligand-mediated EphA2 signaling), increases proliferation of EphA2 expressing cells, increases survival of EphA2 expressing cells, and/or maintains/reconstitutes epithelial and/or endothelial cell layer integrity. The invention also provides pharmaceutical compositions comprising one or more EphA2 antagonistic agents of the invention either alone or in combination with one or more other agents useful for therapy for a hypoproliferative cell disorder. Diagnostic methods and methods for screening for therapeutically useful agents are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 86 USPATFULL on STN  
AN 2005:43296 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PI US 2005037022 A1 20050217  
AI US 2004-816042 A1 20040402 (10)  
RLI Continuation of Ser. No. WO 2002-US31794, filed on 4 Oct 2002, PENDING  
PRAI US 2001-327281P 20011005 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 17090

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using



these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 86 USPATFULL on STN  
AN 2005:30345 USPATFULL  
TI Capsular polysaccharide adhesin antigen, preparation, purification and use  
IN Pier, Gerald B., Brookline, MA, UNITED STATES  
PA The Brigham And Women's Hospital, Inc., Boston, MA, 02115 (U.S. corporation)  
PI US 2005025775 A1 20050203  
AI US 2004-856123 A1 20040528 (10)  
RLI Continuation of Ser. No. US 2002-93582, filed on 8 Mar 2002, GRANTED, Pat. No. US 6743431 Division of Ser. No. US 1999-393832, filed on 10 Sep 1999, GRANTED, Pat. No. US 6399066 Division of Ser. No. US 1994-336688, filed on 7 Nov 1994, GRANTED, Pat. No. US 5980910 Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, ABANDONED Continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, ABANDONED Division of Ser. No. US 1988-250417, filed on 28 Sep 1988, GRANTED, Pat. No. US 5055455  
DT Utility  
FS APPLICATION  
LREP Patrick R.H. Waller, WOLF GREENFIELD & SACKS PC, 600 Atlantic Avenue, Boston, MA, 02210-2211  
CLMN Number of Claims: 5  
ECL Exemplary Claim: CLM-01-30  
DRWN 5 Drawing Page(s)  
LN.CNT 788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymorphic medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 86 USPATFULL on STN  
AN 2005:10558 USPATFULL  
TI Multi-phase, multi-compartment capsular delivery apparatus and methods for using same  
IN Miller, Fred H., Tampa, FL, UNITED STATES  
PI US 2005008690 A1 20050113  
AI US 2004-804576 A1 20040319 (10)  
RLI Continuation-in-part of Ser. No. WO 2003-US10816, filed on 9 Apr 2003, PENDING  
PRAI US 2002-371448P 20020410 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007  
CLMN Number of Claims: 118  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 6126

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of

a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 86 USPATFULL on STN  
AN 2005:10484 USPATFULL  
TI Recombinant human interferon-beta-1b polypeptides  
IN Nestaas, Eirik, San Francisco, CA, UNITED STATES  
Pungor, Erno, Millbrae, CA, UNITED STATES  
PA Schering Aktiengesellschaft, Berlin, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)  
PI US 2005008616 A1 20050113  
AI US 2004-886414 A1 20040706 (10)  
PRAI US 2003-486657P 20030711 (60)  
DT Utility  
FS APPLICATION  
LREP BERLEX BIOSCIENCES, PATENT DEPARTMENT, 2600 HILLTOP DRIVE, P.O. BOX 4099, RICHMOND, CA, 94804-0099  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 1658

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to recombinant human interferon- $\beta$ -1b ("IFN- $\beta$ -1b") polypeptides, or fragments, analogs, derivatives, or variants thereof, having an improved specific activity. The present invention also relates to pharmaceutical compositions comprising such IFN- $\beta$ -1b polypeptides, or fragments, analogs, derivatives, or variants thereof, useful for treating multiple sclerosis. The present invention further relates to methods of producing such IFN- $\beta$ -1b compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 86 USPATFULL on STN  
AN 2004:306557 USPATFULL  
TI Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections  
IN Moussy, Alain, Paris, FRANCE  
Kinet, Jean-Pierre, Lexington, MA, UNITED STATES  
PI US 2004241226 A1 20041202  
AI US 2004-490287 A1 20040322 (10)  
WO 2002-IB4251 20020920  
PRAI US 2001-323313P 20010920 (60)  
DT Utility  
FS APPLICATION  
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 829

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for treating bacterial infections, preferably infections caused by FimH expressing bacteria, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote detach of IL-3 dependent cells cultured to presence of IL-3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 86 USPATFULL on STN  
AN 2004:286238 USPATFULL  
TI Novel multifunctional adhesin proteins and their display in microbial cells  
IN Schembri, Mark Andrew, Skovlunde, DENMARK  
Klemm, Per, Naerum, DENMARK  
PA GYRE LTD., London, UNITED KINGDOM, SE1 6LN (non-U.S. corporation)  
PI US 2004224400 A1 20041111  
AI US 2003-681381 A1 20031009 (10)  
RLI Continuation of Ser. No. US 1999-301704, filed on 29 Apr 1999, ABANDONED  
PRAI DK 1998-598 19980430  
US 1998-83794P 19980501 (60)  
DT Utility  
FS APPLICATION  
LREP HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Page(s)  
LN.CNT 1557

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant cells expressing a multifunctional adhesin protein derived from a naturally occurring adhesin, containing a binding domain that is capable of binding to an organic receptor and a binding domain that is capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind. The cells or modified adhesin proteins, optionally in immobilized form, are useful for separating organic and inorganic compounds including toxic or precious metals from an environment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 29 OF 86 USPATFULL on STN  
AN 2004:233765 USPATFULL  
TI D-mannose contraceptives  
IN Benedict, Dale L., Fayetteville, AR, UNITED STATES  
Benedict, Martha J., Fayetteville, AR, UNITED STATES  
PI US 2004180839 A1 20040916  
AI US 2004-810522 A1 20040326 (10)  
RLI Continuation of Ser. No. US 2002-231399, filed on 29 Aug 2002, GRANTED, Pat. No. US 6753319  
DT Utility  
FS APPLICATION  
LREP Steven Thrasher, 391 Sandhill Dr., Richardson, TX, 75080  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 159

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the use of D-mannose to prevent or inhibit uniting of sperm and egg in the conception process. The administration of D-Mannose to a female such that the environment of an egg has sufficient D-Mannose to inhibit interaction of sperm and the egg and prevent or inhibit conception. D-Mannose dosages may be complimentary to other methods of birth control to enhance their effectiveness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 86 USPATFULL on STN  
AN 2004:221354 USPATFULL  
TI ALBUMIN FUSION PROTEINS  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PI US 2004171123 A1 20040902  
US 6926898 B2 20050809

AI US 2001-832929 A1 20010412 (9)

DT Utility

FS APPLICATION

LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW,  
WASHINGTON, DC, 20005

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 17424

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 86 USPATFULL on STN

AN 2004:203036 USPATFULL

TI Plant proanthocyanidin extract effective at inhibiting utility

IN Howell, Amy B., Hamilton, NJ, UNITED STATES

Vorsa, Nicholi, Atco, NJ, UNITED STATES

PA Rutgers, The State University of New Jersey, New Brunswick, NJ (U.S. corporation)

PI US 2004156925 A1 20040812

AI US 2004-772566 A1 20040204 (10)

RLI Division of Ser. No. US 2003-428063, filed on 30 Apr 2003, GRANTED, Pat. No. US 6720353 Division of Ser. No. US 1998-145694, filed on 2 Sep 1998, GRANTED, Pat. No. US 6608102

PRAI US 1997-58307P 19970909 (60)

DT Utility

FS APPLICATION

LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022

CLMN Number of Claims: 90

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 1770

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 86 USPATFULL on STN

AN 2004:196404 USPATFULL

TI Strain of micro-organism lactobacillus fermentum me-3 as novel anti-microbial and anti-oxidative probiotic

IN Mikelsaar, Marika, Tartu, ESTONIA

Zilmer, Mikhel, Tartu, ESTONIA

Kullisaaar, Tiiu, Tartu, ESTONIA

Annuk, Heidi, Tartu, ESTONIA

Songisepp, Epp, Polva, ESTONIA

PI US 2004151708 A1 20040805

AI US 2003-481713 A1 20031222 (10)

WO 2002-EE6 20020621

PRAI EE 2001-200100356 20010629

DT Utility

FS APPLICATION

LREP James G Dilmore, Reed Smith, P O Box 488, Pittsburgh, PA, 15230-0488

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The strain of micro-organism *Lactobacillus fermentum* ME-3 is a novel anti-microbial and anti-oxidative probiotic. It has a high anti-microbial effect on *Escherichia coli*, *Shigella sonnei*, *Staphylococcus aureus*, *Salmonella typhimurium*, and moderate activity against *Helicobacter pylori* strains. The strain of micro-organism possesses Mn-superoxide dismutase and both its lysates and intact cells have high anti-oxidative activity, increasing the glutathione red-ox ratio in blood sera and able to capture toxic hydroxyl radicals. The strain of micro-organism could be used as a probiotic for the production of functional food (yoghurt, cheese) and non-comestibles (tablets, capsules) for the prophylaxis of intestinal and uroinfections, both for the prevention and treatment of chronic diseases, caused by prolonged oxidative stress.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 86 USPATFULL on STN

AN 2004:190686 USPATFULL

TI Method and composition for maintaining urinary tract health in the face of infections

IN Oneal, Joseph, Irving, TX, UNITED STATES

White, Gary, Irving, TX, UNITED STATES

PI US 2004147459 A1 20040729

AI US 2003-691423 A1 20031022 (10)

PRAI US 2002-420696P 20021023 (60)

DT Utility

FS APPLICATION

LREP CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 295

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The sugar mannose has been used to maintain urinary tract health in the face of *E. coli* infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of *Crataeva nurvala*, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 86 USPATFULL on STN

AN 2004:172003 USPATFULL

TI Methods and compositions for inhibiting adhesion by microorganisms

IN Doyle, Ron J., Louisville, KY, UNITED STATES

Cowan, M. M., Cincinnati, OH, UNITED STATES

PI US 2004132164 A1 20040708

AI US 2003-741740 A1 20031218 (10)

RLI Continuation of Ser. No. US 2000-750857, filed on 29 Dec 2000, ABANDONED

PRAI US 1999-173821P 19991230 (60)  
DT Utility  
FS APPLICATION  
LREP Genencor International, Inc., 925 Page Mill Road, Palo Alto, CA,  
94034-1013  
CLMN Number of Claims: 50  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 2653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed generally to compositions and methods for enzymatic reduction of adhesion by a microorganism to cells, tissues, extracellular matrix, teeth, and/or dental prostheses. The compositions of the invention include pharmaceutical compositions and oral care compositions containing an enzyme that can reduce binding of a microbe to a cell, a tissue, or a surface. Suitable enzymes include a polyphenol oxidase and an asparaginase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 86 USPATFULL on STN  
AN 2004:82309 USPATFULL  
TI Combination of probiotics  
IN Mayra-Makinen, Annika, Helsinki, FINLAND  
Suomalainen, Tarja, Helsinki, FINLAND  
Vaarala, Outi, Helsinki, FINLAND  
PI US 2004062758 A1 20040401  
AI US 2003-470151 A1 20031022 (10)  
WO 2002-FI35 20020117

PRAI FI 2001-157 20010125  
DT Utility  
FS APPLICATION  
LREP Nixon & Vanderhye, 8th Floor, 1100 North Glebe Road, Arlington, VA,  
22201-4714  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 827

AB The invention relates to a probiotic combination comprising different combinations of lactobacilli, propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.

L6 ANSWER 36 OF 86 USPATFULL on STN  
AN 2004:13611 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PI US 2004010134 A1 20040115  
AI US 2001-833245 A1 20010412 (9)  
PRAI US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)

DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and

methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 86 USPATFULL on STN  
AN 2003:318724 USPATFULL  
TI Treatment or prophylaxis of diseases caused by pilus-forming bacteria  
IN Hultgren, Scott, Ballwin, MO, UNITED STATES  
Kuehn, Meta, Berkeley, CA, UNITED STATES  
Xu, Zheng, Blue Bell, PA, UNITED STATES  
Ogg, Derek, Uppsala, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, UNITED STATES  
Kihlberg, Jan, Dalby, SWEDEN  
PI US 2003224468 A1 20031204  
AI US 2001-799680 A1 20010307 (9)  
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, GRANTED, Pat. No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED  
DT Utility  
FS APPLICATION  
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 25 Drawing Page(s)  
LN.CNT 5629

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 38 OF 86 USPATFULL on STN  
AN 2003:312278 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PI US 2003219875 A1 20031127  
US 6905688 B2 20050614  
AI US 2001-833118 A1 20010412 (9)  
PRAI US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid

molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 86 USPATFULL on STN  
AN 2003:289203 USPATFULL  
TI Plant proanthocyanidin extract effective at inhibiting  
IN Howell, Amy B., Hammonton, NJ, UNITED STATES  
Vorsa, Nicholi, Atco, NJ, UNITED STATES  
PA Rutgers, The State University of New Jersey, New Brunswick, NJ, UNITED STATES (U.S. corporation)  
PI US 2003203962 A1 20031030  
US 6720353 B2 20040413  
AI US 2003-428063 A1 20030430 (10)  
RLI Division of Ser. No. US 1998-145694, filed on 2 Sep 1998, GRANTED, Pat. No. US 6608102  
PRAI US 1997-58307P 19970909 (60)  
DT Utility  
FS APPLICATION  
LREP HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022  
CLMN Number of Claims: 90  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 1768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 40 OF 86 USPATFULL on STN  
AN 2003:282728 USPATFULL  
TI Mutant proteins, high potency inhibitory antibodies and fimch crystal structure  
IN Langermann, Solomon, Baltimore, MD, UNITED STATES  
Hultgren, Scott J., Town and Country, MO, UNITED STATES  
Hung, Chia-Suei, St. Louis, MO, UNITED STATES  
Bouckaert, Julie, St. Louis, MO, UNITED STATES  
PI US 2003199071 A1 20031023  
AI US 2001-15085 A1 20011210 (10)  
PRAI US 2000-254353P 20001208 (60)  
US 2001-301878P 20010629 (60)  
DT Utility  
FS APPLICATION  
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 47 Drawing Page(s)



LN.CNT 6520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species, especially human patients, with variants of the E. coli FimCH protein that elicit antibodies that have better functional inhibitory activity than antibodies raised against wild type protein. In particular, such variants include mutations that promote a more open confirmation of the FimH protein, particularly in regions involved in mannose binding, to expose regions previously poorly exposed and mutations that abolish a significantly reduce mannose binding. In another aspect, the invention provides antibodies against such proteins and protein complexes that may be used in passive immunization to protect or treat pathogenic bacterial infections. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of FimCH bound to mannose, and subsets thereof, and methods of using the crystal structure to provide candidate amino acid residues for mutation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 86 USPATFULL on STN  
AN 2003:282700 USPATFULL  
TI Albumin fusion proteins  
IN Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES  
PI US 2003199043 A1 20031023  
AI US 2001-832501 A1 20010412 (9)  
PRAI US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 60  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 14339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 86 USPATFULL on STN  
AN 2003:282649 USPATFULL  
TI Treatment or prophylaxis of diseases caused by pilus-forming bacteria  
IN Hultgren, Scott, Ballwin, MO, UNITED STATES  
Kuehn, Meta, Berkeley, CA, UNITED STATES  
Xu, Zheng, Blue Bell, PA, UNITED STATES  
Ogg, Derek, Stockholm, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, UNITED STATES  
Kihlberg, Jan, Dalby, SWEDEN  
PI US 2003198992 A1 20031023

AI US 2001-798932 A1 20010306 (9)  
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, GRANTED, Pat.  
No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 18 Nov  
1994, PENDING Continuation-in-part of Ser. No. US 1993-154035, filed on  
18 Nov 1993, ABANDONED  
DT Utility  
FS APPLICATION  
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA,  
VA, 22313-1404  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Page(s)  
LN.CNT 5605

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases  
caused by tissue-adhering bacteria are disclosed. By interacting with  
periplasmic molecular chaperones it is achieved that the assembly of  
pili is prevented or inhibited and thereby the infectivity of the  
bacteria is diminished. Also disclosed are methods for screening for  
drugs as well as methods for the de novo design of such drugs, methods  
which rely on novel computer drug modelling methods involving an  
approximative calculation of binding free energy between macromolecules.  
Finally, novel pyranosides which are believed to be capable of  
interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 43 OF 86 USPATFULL on STN  
AN 2003:244853 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES  
PI US 2003171267 A1 20030911  
AI US 2001-833117 A1 20010412 (9)  
PRAI US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 59  
ECL Exemplary Claim: 1  
DRWN 20 Drawing Page(s)  
LN.CNT 13208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid  
molecules encoding the albumin fusion proteins of the invention are also  
encompassed by the invention, as are vectors containing these nucleic  
acids, host cells transformed with these nucleic acids vectors, and  
methods of making the albumin fusion proteins of the invention and using  
these nucleic acids, vectors, and/or host cells. Additionally the  
present invention encompasses pharmaceutical compositions comprising  
albumin fusion proteins and methods of treating, preventing,  
or ameliorating diseases, disorders or conditions using albumin fusion  
proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 44 OF 86 USPATFULL on STN  
AN 2003:222129 USPATFULL  
TI Plant proanthocyanidin extract effective at inhibiting adherence of  
bacteria with P-type fimbriae to surfaces  
IN Howell, Amy B., Hammonton, NJ, United States  
Vorsa, Nicholi, Atco, NJ, United States  
PA Rutgers, the State University of New Jersey, New Brunswick, NJ, United  
States (U.S. corporation)  
PI US 6608102 B1 20030819

AI US 1998-145694 19980902 (9)  
PRAI US 1997-58307P 19970909 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Solola, Taofiq  
LREP Hale and Dorr LLP  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 1377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 86 USPATFULL on STN  
AN 2003:206834 USPATFULL  
TI Chemokine beta-1 fusion proteins  
IN Bell, Adam, Germantown, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2003143191 A1 20030731  
AI US 2002-153604 A1 20020524 (10)  
PRAI US 2001-293212P 20010525 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Page(s)  
LN.CNT 15446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck $\beta$ -1 or Ckbl) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1- $\gamma$ , and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckbl polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 86 USPATFULL on STN  
AN 2003:200465 USPATFULL  
TI Method of administering FimH protein as a vaccine for urinary tract infections  
IN Langermann, Solomon, Baltimore, MD, UNITED STATES  
Ballou, W. Ripley, JR., Silver Springs, MD, UNITED STATES  
PA MedImmune, Inc. (U.S. corporation)  
PI US 2003138449 A1 20030724  
AI US 2002-306897 A1 20021127 (10)  
RLI Continuation of Ser. No. US 2000-724397, filed on 28 Nov 2000, ABANDONED  
PRAI US 2000-226146P 20000818 (60)  
DT Utility

FS APPLICATION  
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711  
CLMN Number of Claims: 209  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Page(s)  
LN.CNT 3107

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of stimulating an immune response in a primate utilizing compositions comprising bacterial adhesin proteins and/or immunogenic fragments thereof. The compositions are useful for the prevention and treatment of bacterial induced diseases involving bacterial adherence to a target cell, such as diseases of the urinary tract. More specifically, the invention relates to the vaccination of primates, preferably humans, with protein complexes, such as a purified FimH polypeptides, a purified FimC-FimH (FimCH) polypeptide complex, or immunogenic fragments thereof, to stimulate protective immunity in the recipient against infection by pathogenic bacteria, including all types of Enterobacteriaceae, preferably E. coli to produce specific immunoglobulin molecules in the serum and urine or mucosal secretions of the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 86 USPATFULL on STN  
AN 2003:181414 USPATFULL  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PI US 2003125247 A1 20030703  
AI US 2001-833041 A1 20010412 (9)  
PRAI US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 20 Drawing Page(s)  
LN.CNT 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 48 OF 86 USPATFULL on STN  
AN 2003:180804 USPATFULL  
TI Novel proteins involved in the synthesis and assembly of O-antigen in pseudomonas aeruginosa  
IN Lam, Joseph S., Guelph, CANADA  
Burrows, Lori L., Guelph, CANADA  
Charter, Deborah, Guelph, CANADA  
Kievit, Teresa de, Guelph, CANADA  
PA University of Guelph (non-U.S. corporation)  
PI US 2003124634 A1 20030703  
AI US 2002-216209 A1 20020812 (10)  
RLI Continuation of Ser. No. US 1999-352994, filed on 13 Jul 1999, ABANDONED  
Division of Ser. No. US 1997-846762, filed on 30 Apr 1997, GRANTED, Pat. No. US 5994072  
PRAI US 1996-16510P 19960430 (60)

US 1997-39473P 19970227 (60)

DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 63 Drawing Page(s)  
LN.CNT 6959

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel nucleic acid molecules encoding proteins involved in the synthesis and assembly of O-antigen in *P. aeruginosa*; and novel proteins encoded by the nucleic acid molecules are described. Methods are disclosed for detecting *P. aeruginosa* in a sample by determining the presence of the proteins or a nucleic acid molecule encoding the proteins in the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 49 OF 86 USPATFULL on STN  
AN 2003:106731 USPATFULL  
TI D-Mannose contraceptives  
IN Benedict, Dale L., Fayetteville, AR, UNITED STATES  
PI US 2003073643 A1 20030417  
US 6753319 B2 20040622  
AI US 2002-231399 A1 20020829 (10)  
PRAI US 2001-315661P 20010829 (60)  
DT Utility  
FS APPLICATION  
LREP Daniel S. Hodgins, Jackson Walker L.L.P., 112 E. Pecan, Ste. 2100, San Antonio, TX, 78205  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 161

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the use of D-Mannose to prevent or inhibit uniting of sperm and egg in the conception process. The administration of D-Mannose to a female such that the environment of an egg has sufficient D-Mannose to inhibit interaction of sperm and the egg and prevent or inhibit conception. D-Mannose dosages may be complimentary to other methods of birth control to enhance their effectiveness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 50 OF 86 USPATFULL on STN  
AN 2003:65335 USPATFULL  
TI 67 Human secreted proteins  
IN Ruben, Steven M., Olney, MD, UNITED STATES  
Ferrie, Ann M., Tewksbury, MA, UNITED STATES  
Rosen, Craig A., Laytonville, MD, UNITED STATES  
Florence, Kimberly A., Rockville, MD, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Florence, Charles, Rockville, MD, UNITED STATES  
Young, Paul E., Gaithersburg, MD, UNITED STATES  
Ni, Jian, Rockville, MD, UNITED STATES  
Endress, Gregory A., Potomac, MD, UNITED STATES  
Feng, Ping, Gaithersburg, MD, UNITED STATES  
Janat, Fouad, Westerly, RI, UNITED STATES  
PI US 2003045459 A1 20030306  
AI US 2001-813153 A1 20010321 (9)  
RLI Continuation of Ser. No. US 1999-363044, filed on 29 Jul 1999, ABANDONED  
Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999,  
UNKNOWN  
PRAI US 1998-73160P 19980130 (60)  
US 1998-73159P 19980130 (60)  
US 1998-73165P 19980130 (60)

US 1998-73164P 19980130 (60)  
US 1998-73167P 19980130 (60)  
US 1998-73162P 19980130 (60)  
US 1998-73161P 19980130 (60)  
US 1998-73170P 19980130 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 14136

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 86 USPATFULL on STN

AN 2003:37487 USPATFULL

TI Secreted Protein HODAZ50

IN RUBEN, STEVEN M., OLNEY, MD, UNITED STATES

ROSEN, CRAIG A., LAYTONSVILLE, MD, UNITED STATES

FISCHER, CARRIE L., BURKE, VA, UNITED STATES

SOPPET, DANIEL R., CENTREVILLE, MD, UNITED STATES

CARTER, KENNETH C., POTOMAC, MD, UNITED STATES

BEDNARIK, DANIEL R., COLUMBIA, MD, UNITED STATES

ENDRESS, GREGORY A., POTOMAC, MD, UNITED STATES

YU, GUO-LIANG, SAN MATEO, CA, UNITED STATES

NI, JIAN, ROCKVILLE, MD, UNITED STATES

FENG, PING, GAITHERSBURG, MD, UNITED STATES

YOUNG, PAUL E., GAITHERSBURG, MD, UNITED STATES

GREENE, JOHN M., GAITHERSBURG, MD, UNITED STATES

FERRIE, ANN M., TEWKSBURY, MA, UNITED STATES

DUAN, ROXANNE, BETHESDA, MD, UNITED STATES

HU, JING-SHAN, SUNNYVALE, CA, UNITED STATES

FLORENCE, KIMBERLY A., ROCKVILLE, MD, UNITED STATES

OLSEN, HENRIK S., GAITHERSBURG, MD, UNITED STATES

EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES

BREWER, LAURIE A., ST. PAUL, MN, UNITED STATES

SHI, YANGGU, GAITHERSBURG, MD, UNITED STATES

PI US 2003027132 A1 20030206

US 6590075 B2 20030708

AI US 1998-148545 A1 19980904 (9)

RLI Continuation-in-part of Ser. No. WO 1998-US4482, filed on 6 Mar 1998,  
PENDING

PRAI US 1997-40162P 19970307 (60)

US 1997-40333P 19970307 (60)

US 1997-38621P 19970307 (60)

US 1997-40161P 19970307 (60)

US 1997-40626P 19970307 (60)

US 1997-40334P 19970307 (60)

US 1997-40336P 19970307 (60)

US 1997-40163P 19970307 (60)

US 1997-47600P 19970523 (60)

US 1997-47615P 19970523 (60)

US 1997-47597P 19970523 (60)

US 1997-47502P 19970523 (60)

US 1997-47633P 19970523 (60)

US 1997-47583P 19970523 (60)

US 1997-47617P 19970523 (60)

US 1997-47618P 19970523 (60)

US 1997-40162P 19970307 (60)

US 1997-40333P 19970307 (60)

US 1997-38621P	19970307 (60)
US 1997-40161P	19970307 (60)
US 1997-40626P	19970307 (60)
US 1997-40334P	19970307 (60)
US 1997-40336P	19970307 (60)
US 1997-40163P	19970307 (60)
US 1997-47615P	19970523 (60)
US 1997-47600P	19970523 (60)
US 1997-47597P	19970523 (60)
US 1997-47502P	19970523 (60)
US 1997-47633P	19970523 (60)
US 1997-47583P	19970523 (60)
US 1997-47617P	19970523 (60)
US 1997-47618P	19970523 (60)
US 1997-47503P	19970523 (60)
US 1997-47592P	19970523 (60)
US 1997-47581P	19970523 (60)
US 1997-47584P	19970523 (60)
US 1997-47500P	19970523 (60)
US 1997-47587P	19970523 (60)
US 1997-47492P	19970523 (60)
US 1997-47598P	19970523 (60)
US 1997-47613P	19970523 (60)
US 1997-47582P	19970523 (60)
US 1997-47596P	19970523 (60)
US 1997-47612P	19970523 (60)
US 1997-47632P	19970523 (60)
US 1997-47601P	19970523 (60)
US 1997-43580P	19970411 (60)
US 1997-43568P	19970411 (60)
US 1997-43314P	19970411 (60)
US 1997-43569P	19970411 (60)
US 1997-43311P	19970411 (60)
US 1997-43671P	19970411 (60)
US 1997-43674P	19970411 (60)
US 1997-43669P	19970411 (60)
US 1997-43312P	19970411 (60)
US 1997-43313P	19970411 (60)
US 1997-43672P	19970411 (60)
US 1997-43315P	19970411 (60)
US 1997-48974P	19970606 (60)
US 1997-56886P	19970822 (60)
US 1997-56877P	19970822 (60)
US 1997-56889P	19970822 (60)
US 1997-56893P	19970822 (60)
US 1997-56630P	19970822 (60)
US 1997-56878P	19970822 (60)
US 1997-56662P	19970822 (60)
US 1997-56872P	19970822 (60)
US 1997-56882P	19970822 (60)
US 1997-56637P	19970822 (60)
US 1997-56903P	19970822 (60)
US 1997-56888P	19970822 (60)
US 1997-56879P	19970822 (60)
US 1997-56880P	19970822 (60)
US 1997-56894P	19970822 (60)
US 1997-56911P	19970822 (60)
US 1997-56636P	19970822 (60)
US 1997-56874P	19970822 (60)
US 1997-56910P	19970822 (60)
US 1997-56864P	19970822 (60)
US 1997-56631P	19970822 (60)
US 1997-56845P	19970822 (60)
US 1997-56892P	19970822 (60)
US 1997-47595P	19970523 (60)
US 1997-57761P	19970905 (60)
US 1997-47599P	19970523 (60)
US 1997-47588P	19970523 (60)
US 1997-47585P	19970523 (60)

US 1997-47586P	19970523 (60)
US 1997-47590P	19970523 (60)
US 1997-47594P	19970523 (60)
US 1997-47589P	19970523 (60)
US 1997-47593P	19970523 (60)
US 1997-47614P	19970523 (60)
US 1997-43578P	19970411 (60)
US 1997-43576P	19970411 (60)
US 1997-47501P	19970523 (60)
US 1997-43670P	19970411 (60)
US 1997-56632P	19970822 (60)
US 1997-56664P	19970822 (60)
US 1997-56876P	19970822 (60)
US 1997-56881P	19970822 (60)
US 1997-56909P	19970822 (60)
US 1997-56875P	19970822 (60)
US 1997-56862P	19970822 (60)
US 1997-56887P	19970822 (60)
US 1997-56908P	19970822 (60)
US 1997-48964P	19970606 (60)
US 1997-57650P	19970905 (60)
US 1997-56884P	19970822 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 13942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 86 USPATFULL on STN

AN 2002:294626 USPATFULL

TI Secreted protein HRGDF73

IN Ruben, Steven M., Olney, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

Fischer, Carrie L., Burke, VA, UNITED STATES

Soppet, Daniel R., Centreville, VA, UNITED STATES

Carter, Kenneth C., North Potomac, MD, UNITED STATES

Bednarik, Daniel P., Columbia, MD, UNITED STATES

Endress, Gregory A., Potomac, MD, UNITED STATES

Yu, Guo-Liang, Berkeley, CA, UNITED STATES

Ni, Jian, Rockville, MD, UNITED STATES

Feng, Ping, Gaithersburg, MD, UNITED STATES

Young, Paul E., Gaithersburg, MD, UNITED STATES

Greene, John M., Gaithersburg, MD, UNITED STATES

Ferrie, Ann M., Tewksbury, MA, UNITED STATES

Duan, Roxanne, Bethesda, MD, UNITED STATES

Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES

Florence, Kimberly A., Rockville, MD, UNITED STATES

Olsen, Henrik S., Gaithersburg, MD, UNITED STATES

Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

Brewer, Laurie A., St. Paul, MN, UNITED STATES

Shi, Yanggu, Gaithersburg, MD, UNITED STATES

PI US 2002164669 A1 20021107

AI US 2001-981876 A1 20011019 (9)

RLI Division of Ser. No. US 2000-621011, filed on 20 Jul 2000, PENDING

PRAI WO 1998-US4482 19980306

US 1997-40162P 19970307 (60)

US 1997-40333P 19970307 (60)



US 1997-38621P	19970307 (60)
US 1997-40161P	19970307 (60)
US 1997-40626P	19970307 (60)
US 1997-40334P	19970307 (60)
US 1997-40336P	19970307 (60)
US 1997-40163P	19970307 (60)
US 1997-47615P	19970523 (60)
US 1997-47600P	19970523 (60)
US 1997-47597P	19970523 (60)
US 1997-47502P	19970523 (60)
US 1997-47633P	19970523 (60)
US 1997-47583P	19970523 (60)
US 1997-47617P	19970523 (60)
US 1997-47618P	19970523 (60)
US 1997-47503P	19970523 (60)
US 1997-47592P	19970523 (60)
US 1997-47581P	19970523 (60)
US 1997-47584P	19970523 (60)
US 1997-47500P	19970523 (60)
US 1997-47587P	19970523 (60)
US 1997-47492P	19970523 (60)
US 1997-47598P	19970523 (60)
US 1997-47613P	19970523 (60)
US 1997-47582P	19970523 (60)
US 1997-47596P	19970523 (60)
US 1997-47612P	19970523 (60)
US 1997-47632P	19970523 (60)
US 1997-47601P	19970523 (60)
US 1997-43580P	19970411 (60)
US 1997-43568P	19970411 (60)
US 1997-43314P	19970411 (60)
US 1997-43569P	19970411 (60)
US 1997-43311P	19970411 (60)
US 1997-43671P	19970411 (60)
US 1997-43674P	19970411 (60)
US 1997-43669P	19970411 (60)
US 1997-43312P	19970411 (60)
US 1997-43313P	19970411 (60)
US 1997-43672P	19970411 (60)
US 1997-43315P	19970411 (60)
US 1997-48974P	19970606 (60)
US 1997-56886P	19970822 (60)
US 1997-56877P	19970822 (60)
US 1997-56889P	19970822 (60)
US 1997-56893P	19970822 (60)
US 1997-56630P	19970822 (60)
US 1997-56878P	19970822 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 74

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 13983

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 53 OF 86 USPATFULL on STN

AN 2002:265556 USPATFULL

TI Treatment or prophylaxis of diseases caused by pilus-forming bacteria

IN Hultgren, Scott, Ballwin, MO, UNITED STATES  
Kuehn, Meta, Berkeley, CA, UNITED STATES  
Xu, Zheng, Blue Bell, PA, UNITED STATES  
Ogg, Derek, Stockholm, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, UNITED STATES  
Kihlberg, Jan, Dalby, SWEDEN  
PI US 2002146428 A1 20021010  
US 6962791 B2 20051108  
AI US 2001-799608 A1 20010307 (9)  
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING  
Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN  
Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993,  
ABANDONED  
DT Utility  
FS APPLICATION  
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O.  
Box 1404, Alexandria, VA, 22313-1404  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 25 Drawing Page(s)  
LN.CNT 5621  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel methods for the treatment and/or prophylaxis of diseases  
caused by tissue-adhering bacteria are disclosed. By interacting with  
periplasmic molecular chaperones it is achieved that the assembly of  
pili is prevented or inhibited and thereby the infectivity of the  
bacteria is diminished. Also disclosed are methods for screening for  
drugs as well as methods for the de novo design of such drugs, methods  
which rely on novel computer drug modelling methods involving an  
approximative calculation of binding free energy between macromolecules.  
Finally, novel pyranosides which are believed to be capable of  
interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 86 USPATFULL on STN  
AN 2002:174960 USPATFULL  
TI Compounds and pharmaceutical compositions for the treatment  
and prophylaxis of bacterial infections  
IN Hultgren, Scott, Ballwin, MO, United States  
Kuehn, Meta, Berkeley, CA, United States  
Xu, Zheng, Blue Bell, PA, United States  
Ogg, Derek, Uppsala, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, United States  
Kihlberg, Jan, Dalby, SWEDEN  
PA Washington University, St. Louis, MO, United States (U.S. corporation)  
Siga Pharmaceuticals, Inc., Corvallis, OR, United States (U.S.  
corporation)  
PI US 6420127 B1 20020716  
WO 9514028 19950526  
AI US 1996-640877 19961010 (8)  
WO 1994-US13455 19941118  
19961010 PCT 371 date  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Swartz, Rodney P  
LREP Burns, Doane, Swecker & Mathis, L.L.P.  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 35 Drawing Figure(s); 25 Drawing Page(s)  
LN.CNT 5398  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel methods for the treatment and/or prophylaxis of diseases  
caused by tissue-adhering bacteria are disclosed. By interacting with  
periplasmic molecular chaperones it is achieved that the assembly of

pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 55 OF 86 USPATFULL on STN  
AN 2002:129527 USPATFULL  
TI Capsular polysaccharide adhesin antigen, preparation, purification and use  
IN Pier, Gerald B., Brookline, MA, United States  
PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)  
PI US 6399066 B1 20020604  
AI US 1999-393832 19990910 (9)  
RLI Division of Ser. No. US 1994-336688, filed on 7 Nov 1994, now patented, Pat. No. US 5980910 Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, now abandoned Continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, now abandoned Division of Ser. No. US 1988-250417, filed on 28 Sep 1988, now patented, Pat. No. US 5055455  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Graser, Jennifer E.  
LREP Wolf, Greenfield and Sacks, P.C.  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 86 USPATFULL on STN  
AN 2002:126346 USPATFULL  
TI COMPOSITIONS INCLUDING GLYCOSAMINOGLYCANS DEGRADING ENZYMES AND USE OF SAME AGAINST SURFACE PROTECTED BACTERIA  
IN YACOBY-ZEEVI, ORON, MEITAR, ISRAEL  
PI US 2002064858 A1 20020530  
US 6423312 B2 20020723  
AI US 1998-140888 A1 19980827 (9)  
RLI Continuation of Ser. No. US 1998-46475, filed on 25 Mar 1998, PATENTED Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, PATENTED  
DT Utility  
FS APPLICATION  
LREP Sol Steinbein, G. E. Ehrlich Ltd, c/o Anthony Castorina, 2001 Jefferson Davis Highway Ste. 207, Arlington, VA, 22202  
CLMN Number of Claims: 41  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN.CNT 1131

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of rendering a surface protected bacteria more susceptible to

an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 57 OF 86 USPATFULL on STN  
AN 2002:85159 USPATFULL  
TI Treatment or prophylaxis of diseases caused by pilus-forming  
bacteria  
IN Hultgren, Scott, Ballwin, MO, UNITED STATES  
Kuehn, Meta, Berkeley, CA, UNITED STATES  
Xu, Zheng, Blue Bell, PA, UNITED STATES  
Ogg, Derek, Stockholm, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, UNITED STATES  
Kihlberg, Jan, Dalby, SWEDEN  
PI US 2002045199 A1 20020418  
US 6596504 B2 20030722  
AI US 2001-799540 A1 20010307 (9)  
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING  
Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN  
Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993,  
ABANDONED  
DT Utility  
FS APPLICATION  
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O.  
Box 1404, Alexandria, VA, 22313-1404  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 25 Drawing Page(s)  
LN.CNT 5601

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases  
caused by tissue-adhering bacteria are disclosed. By interacting with  
periplasmic molecular chaperones it is achieved that the assembly of  
pili is prevented or inhibited and thereby the infectivity of the  
bacteria is diminished. Also disclosed are methods for screening for  
drugs as well as methods for the de novo design of such drugs, methods  
which rely on novel computer drug modelling methods involving an  
approximative calculation of binding free energy between macromolecules.  
Finally, novel pyranosides which are believed to be capable of  
interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 86 USPATFULL on STN  
AN 2002:60940 USPATFULL  
TI Treatment or prophylaxis of diseases caused by pilus-forming  
bacteria  
IN Hultgren, Scott, Ballwin, MO, UNITED STATES  
Kuehn, Meta, Berkeley, CA, UNITED STATES  
Xu, Zheng, Blue Bell, PA, UNITED STATES  
Ogg, Derek, Stockholm, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, UNITED STATES  
Kihlberg, Jan, Dalby, SWEDEN  
PI US 2002034774 A1 20020321  
US 6548265 B2 20030415  
AI US 2001-799576 A1 20010307 (9)  
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING  
Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN  
Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993,  
ABANDONED  
DT Utility  
FS APPLICATION  
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O.  
Box 1404, Alexandria, VA, 22313-1404

CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 25 Drawing Page(s)  
LN.CNT 5543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 59 OF 86 USPATFULL on STN  
AN 2002:16560 USPATFULL  
TI Methods and compositions for inhibiting adhesion by microorganisms  
IN Doyle, Ron J., Louisville, KY, UNITED STATES  
Cowan, M. M., Cincinnati, OH, UNITED STATES  
PI US 2002009436 A1 20020124  
AI US 2000-750857 A1 20001229 (9)  
PRAI US 1999-173821P 19991230 (60)  
DT Utility  
FS APPLICATION  
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903  
CLMN Number of Claims: 50  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 2655

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed generally to compositions and methods for enzymatic reduction of adhesion by a microorganism to cells, tissues, extracellular matrix, teeth, and/or dental prostheses. The compositions of the invention include pharmaceutical compositions and oral care compositions containing an enzyme that can reduce binding of a microbe to a cell, a tissue, or a surface. Suitable enzymes include a polyphenol oxidase and an asparaginase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 60 OF 86 USPATFULL on STN  
AN 2001:170867 USPATFULL  
TI Colorimetric glycopolythiophene biosensors  
IN Charych, Deborah J., Albony, CA, United States  
Myung-Gi-Baek, Ottawa, Canada  
PA The Regents of the University of California (U.S. corporation)  
PI US 2001026915 A1 20011004  
US 6660484 B2 20031209  
AI US 2000-734410 A1 20001211 (9)  
RLI Continuation-in-part of Ser. No. US 1999-461509, filed on 14 Dec 1999, PENDING Division of Ser. No. US 1996-592724, filed on 26 Jan 1996, GRANTED, Pat. No. US 6001556 Continuation-in-part of Ser. No. US 1993-159927, filed on 30 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-976697, filed on 13 Nov 1992, ABANDONED Continuation-in-part of Ser. No. US 2000-500295, filed on 8 Feb 2000, PENDING Division of Ser. No. US 1997-920501, filed on 29 Aug 1997, GRANTED, Pat. No. US 6022748 Continuation-in-part of Ser. No. US 1998-103344, filed on 23 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1996-609312, filed on 1 Mar 1996, GRANTED, Pat. No. US 6183772 Continuation-in-part of Ser. No. US 1995-389475, filed on 13 Feb 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-289384, filed on 11 Aug 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-328237, filed on 24 Oct 1994, ABANDONED Continuation-in-part of Ser. No. US 1997-944323, filed on 6 Oct 1997, GRANTED, Pat. No. US 6180135 Division of Ser. No. US 1995-389475, filed on 13 Feb 1995, ABANDONED

Continuation-in-part of Ser. No. US 1998-23898, filed on 13 Feb 1998,  
PENDING Continuation-in-part of Ser. No. US 1998-33557, filed on 2 Mar  
1998, PENDING Continuation-in-part of Ser. No. US 1999-337973, filed on  
21 Jun 1999, PENDING

PRAI US 1999-170190P 19991210 (60)  
US 1997-50496P 19970623 (60)  
US 1997-38383P 19970214 (60)  
US 1997-39749P 19970303 (60)  
US 1998-90266P 19980622 (60)

DT Utility

FS APPLICATION

LREP MEDLEN & CARROLL, LLP, 220 Montgomery Street, Suite 2200, San Francisco,  
CA, 94104

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)

LN.CNT 2671

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the direct  
detection of analytes using observable spectral changes in biopolymeric  
systems. In particular, the present invention allows for the direct  
colorimetric detection of analytes using color changes that occur in  
glycopolymers in response to selective binding of  
analytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 61 OF 86 USPATFULL on STN

AN 2000:160793 USPATFULL

TI Treatment or prophylaxis of diseases caused by pilus-forming  
bacteria

IN Hultgren, Scott, Ballwin, MO, United States

Kuehn, Meta, Berkeley, CA, United States

Xu, Zheng, Blue Bell, PA, United States

Ogg, Derek, Uppsala, Sweden

Harris, Mark, Uppsala, Sweden

Lepisto, Matti, Lund, Sweden

Kihlberg, Jan, Dalby, Sweden

Jones, Charles Hal, St. Louis, MO, United States

PA SIGA Pharmaceuticals, Inc., New York, NY, United States (U.S.  
corporation)

Washington University, St. Louis, MO, United States (U.S. corporation)

PI US 6153396 20001128

AI US 1995-465275 19950605 (8)

RLI Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 which is a  
continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993,  
now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Swartz, Rodney P.

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 29 Drawing Figure(s); 24 Drawing Page(s)

LN.CNT 5410

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases  
caused by tissue-adhering bacteria are disclosed. By interacting with  
periplasmic molecular chaperones it is achieved that the assembly of  
pili is prevented or inhibited and thereby the infectivity of the  
bacteria is diminished. Also disclosed are methods for screening for  
drugs as well as methods for the de novo design of such drugs, methods  
which rely on novel computer drug modelling methods involving an  
approximative calculation of binding free energy between macromolecules.  
Finally, novel pyranosides which are believed to be capable of  
interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 62 OF 86 USPATFULL on STN  
AN 1999:163678 USPATFULL  
TI Treatment or prophylaxis of diseases caused by pilus-forming  
bacteria  
IN Hultgren, Scott, 1637 Country Hill La., Ballwin, MO, United States  
Kuehn, Meta, 7351 Claremont Ave., #2, Berkeley, CA, United States 94705  
Xu, Zheng, 887 Village Cir., Blue Bell, PA, United States 19422  
Ogg, Derek, Artillerigatan 16B, S-752 37, Uppsala, Sweden  
Harris, Mark, Norbykallvagen 2, S-756 45 Uppsala, Sweden  
Lepisto, Matti, Flygelvaagen 257, S-224 73 Lund, Sweden  
Kihlberg, Jan, Havrevagen 16, S-240 10 Dalby, Sweden  
Jones, Charles Hal, 1104 Moorlands Dr., St. Louis, MO, United States  
63110  
PI US 6001823 19991214  
AI US 1995-462436 19950605 (8)  
RLI Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 which is a  
continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993,  
now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Raymond, Richard L.  
LREP Burns, Doane, Swecker & Mathis, L.L.P.  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 34 Drawing Figure(s); 24 Drawing Page(s)  
LN.CNT 5409  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel methods for the treatment and/or prophylaxis of diseases  
caused by tissue-adhering bacteria are disclosed. By interacting with  
periplasmic molecular chaperones it is achieved that the assembly of  
pili is prevented or inhibited and thereby the infectivity of the  
bacteria is diminished. Also disclosed are methods for screening for  
drugs as well as methods for the de novo design of such drugs, methods  
which rely on novel computer drug modelling methods involving an  
approximative calculation of binding free energy between macromolecules.  
Finally, novel pyranosides which are believed to be capable of  
interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 63 OF 86 USPATFULL on STN  
AN 1999:159997 USPATFULL  
TI Compounds that bind bacterial pili  
IN Shekhani, Mohammed Saleh, Madison, WI, United States  
Firca, Joseph R., Vernon Hills, IL, United States  
Anderson, Byron, Morton Grove, IL, United States  
PA Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S.  
corporation)  
PI US 5998381 19991207  
AI US 1996-760903 19961206 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Peselev, Elli  
LREP Medlen & Carroll, LLP  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 5  
DRWN 23 Drawing Figure(s); 25 Drawing Page(s)  
LN.CNT 6570  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Diagnostics and treatments for bacterial infection are  
disclosed. The treatments prevent bacteria from adhering to  
host cells by interfering with the binding of the bacteria to cell  
receptors. Compounds that inhibit bacterial adherence to cells are  
engineered to be readily modified for best efficacy with different modes  
of treatment. The compounds can be readily modified for use to  
identify bacteria according to their cell binding specificities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 86 USPATFULL on STN  
AN 1999:155456 USPATFULL  
TI Proteins involved in the synthesis and assembly of O-antigen in  
Pseudomonas aeruginosa  
IN Lam, Joseph S., Guelph, Canada  
Burrows, Lori, Guelph, Canada  
Charter, Deborah, Guelph, Canada  
de Kievit, Teresa, Guelph, Canada  
PA University of Guelph, Guelph, Canada (non-U.S. corporation)  
PI US 5994072 19991130  
AI US 1997-846762 19970430 (8)  
PRAI US 1996-16510P 19960430 (60)  
US 1997-39473P 19970227 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Schwartzman, Robert  
LREP Merchant & Gould P.C.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 66 Drawing Figure(s); 63 Drawing Page(s)  
LN.CNT 7459  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel nucleic acid molecules encoding proteins involved in the synthesis  
and assembly of O-antigen in P. aeruginosa; and novel proteins encoded  
by the nucleic acid molecules are described. Methods are disclosed for  
detecting P. aeruginosa in a sample by determining the presence of the  
proteins or a nucleic acid molecule encoding the proteins in the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 86 USPATFULL on STN  
AN 1999:141317 USPATFULL  
TI Capsular polysaccharide adhesion antigen preparation, purification and  
use  
IN Pier, Gerald B., Brookline, MA, United States  
PA Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S.  
corporation)  
PI US 5980910 19991109  
AI US 1994-336688 19941107 (8)  
RLI Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, now  
abandoned which is a continuation of Ser. No. US 1991-727982, filed on  
10 Jul 1991, now abandoned which is a division of Ser. No. US  
1988-250417, filed on 28 Sep 1988, now patented, Pat. No. US 5055455  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Chin, Christopher L.; Assistant Examiner: Graser,  
Jennifer  
LREP Wolf, Greenfield & Sacks, P.C.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 864  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A substantially pure capsular exopolysaccharide adhesin of  
coagulase-negative staphylococcal strains, and a general method to  
prepare such adhesins, are described. Vaccines composed of such  
adhesins, and uses of such adhesins to produce polyclonal and monoclonal  
antibodies against such adhesins, are also disclosed. The adhesins are  
useful in coating polymeric medical materials to prevent colonization by  
coagulase-negative staphylococcal strains, and as a probe in selecting  
desirable polymeric medical materials. Such adhesin antibodies are  
useful in vivo to prevent infection by nosocomial coagulase-negative  
staphylococcal strains, in assays for the detection of such bacteria, in  
assays for the estimation of such adhesins in complex mixtures, and as  
an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 86 USPATFULL on STN



AN 95:110434 USPATFULL  
TI Method for treating galabiose-binding bacteria infections  
IN Magnusson, Hans G., Lund, Sweden  
Kihlberg, Jan O., Malmo, both of, Sweden  
PA Symbicom Aktiebolag, Umea, Sweden (non-U.S. corporation)  
PI US 5474986 19951212  
WO 9001488 19900222  
AI US 1991-689077 19910411 (7)  
WO 1989-DK192 19890811  
19910411 PCT 371 date  
19910411 PCT 102(e) date  
PRAI DK 1988-4550 19880812  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Kunz, Gary  
L.  
LREP Cooper, Iver P.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 10  
DRWN No Drawings  
LN.CNT 1802  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A method for treating infections caused by galabiose-binding  
bacteria using galabiose derivatives modified at the 3' and anomeric  
positions. The galabiose-derivatives and compositions of same are also  
disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 67 OF 86 USPATFULL on STN  
AN 91:82203 USPATFULL  
TI Capsular polysaccharide adhesin antigen, preparation, purification and  
use  
IN Pier, Gerald B., Brookline, MA, United States  
PA Brigham and Women's Hospital, Boston, MA, United States (U.S.  
corporation)  
PI US 5055455 19911008  
AI US 1988-250417 19880928 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Griffin, Ronald W.  
LREP Sterne, Kessler, Goldstein & Fox  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 768  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A substantially pure capsular exopolysaccharide adhesin of  
coagulase-negative staphylococcal strains, and a general method to  
prepare such adhesins, are described. Vaccines composed of such  
adhesins, and uses of such adhesins to produce polyclonal and monoclonal  
antibodies against such adhesins, are also disclosed. The adhesins are  
useful in coating polymeric medical materials to prevent colonization by  
coagulase-negative staphylococcal strains, and as a probe in selecting  
desirable polymeric medical materials. Such adhesin antibodies are  
useful in vivo to prevent infection by nosocomial coagulase-negative  
staphylococcal strains, in assays for the detection of such bacteria, in  
assays for the estimation of such adhesins in complex mixtures, and as  
an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 86 USPATFULL on STN  
AN 90:17708 USPATFULL  
TI Antibiotic tan-749, its derivatives, production and use thereof  
IN Harada, Setsuo, Kawanishi, Japan  
Ono, Hideo, Kobe, Japan  
Masuya, Hirotomo, Kawabe, Japan  
Natsugari, Hideaki, Ashiya, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
PI US 4906659 19900306  
AI US 1987-129737 19871207 (7)  
RLI Continuation-in-part of Ser. No. US 1986-868739, filed on 30 May 1986,  
now abandoned And a continuation-in-part of Ser. No. US 1986-941208,  
filed on 12 Dec 1986, now abandoned  
PRAI JP 1985-133491 19850618  
JP 1985-143711 19850618  
JP 1985-291055 19851223  
JP 1985-289671 19851227  
JP 1986-293879 19861210  
JP 1986-311586 19861226  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Wax, Robert A.  
LREP Wenderoth, Lind & Ponack  
CLMN Number of Claims: 50  
ECL Exemplary Claim: 1,50  
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)  
LN.CNT 6501

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula ##STR1## wherein R.sup.1 and R.sup.4 are independently amino or an organic residue bonded through nitrogen, R.sup.2 is hydrogen or alkyl which may be substituted, R.sup.3 is hydrogen or a protecting group and R5 is hydroxyl which may be substituted or amino which may be substituted or salts thereof; with the proviso that when R.sup.1 is amino, leucylamino, acetylamino or benzyloxycarbonylamino, R.sup.3 is hydrogen, methyl or 2-tetrahydropyranyl, R.sup.4 is amino, acetylamino or benzyloxycarbonylamino and R.sup.5 is hydroxyl which may be substituted or amino which may be substituted, R.sup.2 is alkyl which may be substituted, has antibacterial activities against drug-resistant bacteria and therefore can be useful as a chemotherapeutic drug for bacterial infections in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 69 OF 86 USPATFULL on STN  
AN 89:94265 USPATFULL  
TI Receptor specific proteins and their use in receptor typing  
IN Hull, Richard A., Houston, TX, United States  
Hull, Sheila I., Houston, TX, United States  
Nowicki, Bogdan, Houston, TX, United States  
PA Baylor College of Medicine, Houston, TX, United States (U.S. corporation)  
PI US 4882425 19891121  
AI US 1987-72197 19870709 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Moskowitz, Margaret; Assistant Examiner: Kushan, Jeff  
LREP Fulbright & Jaworski  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1040

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is composition of matter and methods useful for the indentification of blood group antigens. Additionally a kit which can be used to identify and quantify a large number of blood group antigens is disclosed. The composition of matter and the methods can be used to identify antigens on red blood cells, as well as, on tissue samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 70 OF 86 USPATFULL on STN  
AN 88:26156 USPATFULL  
TI Synthetic vaccine against urinary infections  
IN Schmidt, M. Alexander, Palo Alto, CA, United States  
O'Hanley, Peter, Palo Alto, CA, United States

PA Schoolnik, Gary K., Palo Alto, CA, United States  
The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 4740585 19880426  
AI US 1984-635429 19840730 (6)  
DCD 20050405  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Draper, Garnette D.  
LREP Ciotti & Murashige, Irell & Manella  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 582

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A vaccine effective in protecting mammals against urinary  
tract infections is prepared from synthetic peptides  
substantially equivalent to short sequences contained in HU849 pilin  
conjugated to substantially antigenically neutral carriers or from a  
CNBrII fragment of HU849 pilin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 71 OF 86 USPATFULL on STN  
AN 88:21210 USPATFULL  
TI Chemically defined vaccine against urinary infections  
IN O'Hanley, Peter, Palo Alto, CA, United States  
Schoolnik, Gary K., Palo Alto, CA, United States  
Lark, David, Palo Alto, CA, United States  
Falkow, Stanley, Seattle, WA, United States  
PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 4736017 19880405  
AI US 1984-605287 19840430 (6)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Draper, Garnette D.  
LREP Ciotti & Murashige, Irell & Manella  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 672

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A vaccine effective in protecting mammals against urinary infections is  
prepared from purified Gal-Gal pilus proteins or fragments thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 86 USPATFULL on STN  
AN 88:9749 USPATFULL  
TI Vaccine composition for immunization against urinary  
tract infection caused by E. coli  
IN Brinton, Jr., Charles C., Pittsburgh, PA, United States  
Fusco, Peter C., Pittsburgh, PA, United States  
PA Bactex, Inc., Pittsburgh, United States (U.S. corporation)  
PI US 4725435 19880216  
AI US 1986-875473 19860618 (6)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Draper, Garnette D.  
LREP Behr, Omri M.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 449

AB There is provided a vaccine material capable of providing substantial  
levels of protection against urinary tract  
infection caused by Escherichia coli. The protecting means  
comprises pili of organisms having pili of the same pilic family as

those on the infecting organism. Protection is given by administering the pili to the subject to be protected.

L6 ANSWER 73 OF 86 USPATFULL on STN  
AN 84:33028 USPATFULL  
TI Immunization against infection by Escherichia coli  
IN Brinton, Charles C., Pittsburgh, PA, United States  
PA Bactex, Inc., Pittsburgh, PA, United States (U.S. corporation)  
PI US 4454117 19840612  
AI US 1982-417464 19820913 (6)  
DCD 19971202  
RLI Continuation of Ser. No. US 1980-187051, filed on 15 Sep 1980 which is a continuation-in-part of Ser. No. US 1977-854343, filed on 23 Nov 1977, now patented, Pat. No. US 4237115, issued on 2 Dec 1980  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Rosen, Sam  
LREP Behr, Omri M.  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1,5  
DRWN No Drawings  
LN.CNT 504

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a vaccine material capable of providing substantial levels of protection against human disease caused by infection with Escherichia coli. The protecting means comprises pili of the infecting organism. The protection is given either by administering the pili directly to the subject to be protected or to a pregnant or lactating female where protection of the newborn is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 74 OF 86 USPATFULL on STN  
AN 84:33027 USPATFULL  
TI Immunization of humans against enterotoxogenic infection by Escherichia coli  
IN Brinton, Charles C., Pittsburgh, PA, United States  
PA Bactex, Inc., Pittsburgh, PA, United States (U.S. corporation)  
PI US 4454116 19840612  
AI US 1980-187051 19800915 (6)  
DCD 19971202  
RLI Continuation-in-part of Ser. No. US 1977-854343, filed on 23 Nov 1977, now patented, Pat. No. US 4237115  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Hazel, Blondel  
LREP Behr, Omri M.  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 490

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a vaccine material capable of providing substantial levels of protection against human disease caused by infection with Escherichia coli. The protecting means comprises pili of the infecting organism. The protection is given either by administering the pili directly to the subject to be protected or to a pregnant or lactating female where protection of the newborn is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 75 OF 86 USPATFULL on STN  
AN 76:23132 USPATFULL  
TI Process for the preparation of xylostasin  
IN Horii, Satoshi, Osaka, Japan  
Nogami, Ikuo, Kyoto, Japan  
Hasegawa, Toru, Kawani, Japan  
Yoneda, Masahiko, Uozakinaka, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
PI US 3953293 19760427  
AI US 1974-493619 19740731 (5)  
RLI Division of Ser. No. US 1973-362504, filed on 21 May 1973, now abandoned  
PRAI JP 1972-54581 19720531  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Monacell, A. Louis; Assistant Examiner: Wiseman, Thomas G.  
LREP Wenderoth, Lind & Ponack  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel aminoglycoside antibiotic, xylostasin, of the nomenclature O- $\beta$ -D-xylofuranosyl-(1 $\rightarrow$ 5)-O-[ $\alpha$ -2,6-diamino-2,6-dideoxy-D-glucopyranosyl-(1 $\rightarrow$ 4)]-2-deoxystreptamine and its pharmaceutically acceptable acid salts which are effective against infections with bacteria, and a process for producing the antibiotic by cultivating a strain belonging to the genus Bacillus which is capable of producing the antibiotic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 76 OF 86 USPAT2 on STN  
AN 2004:221354 USPAT2  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)  
PI US 6926898 B2 20050809  
AI US 2001-832929 20010412 (9)  
PRAI US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Robinson, Hope A.  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner LLP  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Figure(s); 20 Drawing Page(s)  
LN.CNT 18544

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 77 OF 86 USPAT2 on STN  
AN 2003:312278 USPAT2  
TI Albumin fusion proteins  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)  
PI US 6905688 B2 20050614  
AI US 2001-833118 20010412 (9)  
PRAI US 2000-229358P 20000412 (60)

US 2000-256931P 20001221 (60)  
US 2000-199384P 20000425 (60)

DT Utility  
FS GRANTED

EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Hope A.

LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 21 Drawing Figure(s); 20 Drawing Page(s)

LN.CNT 16530

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 78 OF 86 USPAT2 on STN

AN 2003:289203 USPAT2

TI Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces

IN Howell, Amy B., Hamilton, NJ, United States

Vorsa, Nicholi, Atco, NJ, United States

PA Rutgers, The State University of New Jersey, New Brunswick, NJ, United States (U.S. corporation)

PI US 6720353 B2 20040413

AI US 2003-428063 20030430 (10)

RLI Division of Ser. No. US 1998-145694, filed on 2 Sep 1998, now patented, Pat. No. US 6608102

PRAI US 1997-58307P 19970909 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Solola, Taofiq

LREP Hale and Dorr LLP

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 5 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 1572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 79 OF 86 USPAT2 on STN

AN 2003:106731 USPAT2

TI D-mannose contraceptives

IN Benedict, Dale L., Fayetteville, AR, United States

PA Benedict, Martha, Fayetteville, AR, United States  
BioTech Pharmacal, Inc., Fayetteville, AR, United States (U.S.  
corporation)  
PI US 6753319 B2 20040622  
AI US 2002-231399 20020829 (10)  
PRAI US 2001-315661P 20010829 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Jagoe, Donna  
LREP Jackson Walker, LLP, Miller, Mark H., Nash, William B.  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the use of D-Mannose  
to prevent or inhibit uniting of sperm and egg in the conception  
process. The administration of D-Mannose to a female  
such that the environment of an egg has sufficient D-  
Mannose to inhibit interaction of sperm and the egg and prevent  
or inhibit conception. D-Mannose dosages may be  
complimentary to other methods of birth control to enhance their  
effectiveness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 80 OF 86 USPAT2 on STN  
AN 2003:37487 USPAT2  
TI Secreted protein HODAZ50  
IN Ruben, Steven M., Olney, MD, United States  
Rosen, Craig A., Laytonsville, MD, United States  
Fischer, Carrie L., Burke, VA, United States  
Soppet, Daniel R., Centreville, VA, United States  
Carter, Kenneth C., North Potomac, MD, United States  
Bednarik, Daniel P., Columbia, MD, United States  
Endress, Gregory A., Potomac, MD, United States  
Yu, Guo-Liang, Berkeley, CA, United States  
Ni, Jian, Rockville, MD, United States  
Feng, Ping, Gaithersburg, MD, United States  
Young, Paul E., Gaithersburg, MD, United States  
Greene, John M., Gaithersburg, MD, United States  
Ferrie, Ann M., Tewksbury, MA, United States  
Duan, Roxanne, Bethesda, MD, United States  
Hu, Jing-Shan, Sunnyvale, CA, United States  
Florence, Kimberly A., Rockville, MD, United States  
Olsen, Henrik S., Gaithersburg, MD, United States  
Ebner, Reinhard, Gaithersburg, MD, United States  
Brewer, Laurie A., St. Paul, MN, United States  
Shi, Yanggu, Gaithersburg, MD, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)  
PI US 6590075 B2 20030708  
AI US 1998-148545 19980904 (9)  
PRAI US 1997-40162P 19970307 (60)  
US 1997-40333P 19970307 (60)  
US 1997-38621P 19970307 (60)  
US 1997-40161P 19970307 (60)  
US 1997-40626P 19970307 (60)  
US 1997-40336P 19970307 (60)  
US 1997-40163P 19970307 (60)  
US 1997-47615P 19970523 (60)  
US 1997-47600P 19970523 (60)  
US 1997-47597P 19970523 (60)  
US 1997-47502P 19970523 (60)  
US 1997-47633P 19970523 (60)  
US 1997-47583P 19970523 (60)  
US 1997-47617P 19970523 (60)  
US 1997-47618P 19970523 (60)  
US 1997-47503P 19970523 (60)

US 1997-47592P	19970523 (60)
US 1997-47581P	19970523 (60)
US 1997-47584P	19970523 (60)
US 1997-47500P	19970523 (60)
US 1997-47587P	19970523 (60)
US 1997-47492P	19970523 (60)
US 1997-47598P	19970523 (60)
US 1997-47613P	19970523 (60)
US 1997-47582P	19970523 (60)
US 1997-47612P	19970523 (60)
US 1997-47632P	19970523 (60)
US 1997-47601P	19970523 (60)
US 1997-43580P	19970411 (60)
US 1997-40334P	19970307 (60)
US 1997-47596P	19970523 (60)
US 1997-43311P	19970411 (60)
US 1997-56845P	19970822 (60)
US 1997-56631P	19970822 (60)
US 1997-43568P	19970411 (60)
US 1997-43314P	19970411 (60)
US 1997-43569P	19970411 (60)
US 1997-43671P	19970411 (60)
US 1997-43674P	19970411 (60)
US 1997-43669P	19970411 (60)
US 1997-43312P	19970411 (60)
US 1997-43313P	19970411 (60)
US 1997-43672P	19970411 (60)
US 1997-43315P	19970411 (60)
US 1997-48974P	19970406 (60)
US 1997-56886P	19970822 (60)
US 1997-56877P	19970822 (60)
US 1997-56889P	19970822 (60)
US 1997-56893P	19970822 (60)
US 1997-56630P	19970822 (60)
US 1997-56878P	19970822 (60)
US 1997-56662P	19970822 (60)
US 1997-56872P	19970822 (60)
US 1997-56882P	19970822 (60)
US 1997-56637P	19970822 (60)
US 1997-56903P	19970822 (60)
US 1997-56888P	19970822 (60)
US 1997-56879P	19970822 (60)
US 1997-56880P	19970822 (60)
US 1997-56894P	19970822 (60)
US 1997-56911P	19970822 (60)
US 1997-56636P	19970822 (60)
US 1997-56874P	19970822 (60)
US 1997-56910P	19970822 (60)
US 1997-56864P	19970822 (60)
US 1997-56892P	19970822 (60)
US 1997-47595P	19970523 (60)
US 1997-57761P	19970905 (60)
US 1997-47599P	19970523 (60)
US 1997-47588P	19970523 (60)
US 1997-47585P	19970523 (60)
US 1997-47586P	19970523 (60)
US 1997-47590P	19970523 (60)
US 1997-47594P	19970523 (60)
US 1997-47589P	19970523 (60)
US 1997-47593P	19970523 (60)
US 1997-47614P	19970523 (60)
US 1997-43578P	19970411 (60)
US 1997-43576P	19970411 (60)
US 1997-47501P	19970523 (60)
US 1997-43670P	19970411 (60)
US 1997-56632P	19970822 (60)
US 1997-56664P	19970822 (60)
US 1997-56876P	19970822 (60)
US 1997-56881P	19970822 (60)



US 1997-56909P 19970822 (60)  
US 1997-56875P 19970822 (60)  
US 1997-56862P 19970822 (60)  
US 1997-56887P 19970822 (60)  
US 1997-56908P 19970822 (60)  
US 1997-48964P 19970606 (60)  
US 1997-57650P 19970905 (60)  
US 1997-56884P 19970822 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Hope A.

LREP Human Genome Sciences, Inc.

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 13365

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 81 OF 86 USPAT2 on STN

AN 2002:265556 USPAT2

TI Treatment or prophylaxis of diseases caused by pilus-forming bacteria

IN Hultgren, Scott, Ballwin, MO, UNITED STATES

Kuehn, Meta, Berkeley, CA, UNITED STATES

Xu, Zheng, Blue Bell, PA, UNITED STATES

Ogg, Derek, Uppsala, SWEDEN

Harris, Mark, Uppsala, SWEDEN

Lepisto, Matti, Lund, SWEDEN

Jones, Charles Hal, Saint Louis, MO, UNITED STATES

Kihlberg, Jan, Dalby, SWEDEN

PA Washington University, St. Louis, MO, UNITED STATES (U.S. corporation)

Siga Pharmaceuticals, Inc., New York, NY, UNITED STATES (U.S. corporation)

PI US 6962791 B2 20051108

AI US 2001-799608 20010307 (9)

RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, Pat. No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 8 Nov 1994, PENDING Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED

DT Utility

FS GRANTED

EXNAM Primary Examiner: Swartz, Rodney P

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 35 Drawing Figure(s); 25 Drawing Page(s)

LN.CNT 5365

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 82 OF 86 USPAT2 on STN  
AN 2002:126346 USPAT2  
TI Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria  
IN Yacoby-Zeevi, Oron, Meitar, ISRAEL  
PA Insight Strategy & Marketing Ltd., Rehovot, ISRAEL (non-U.S. corporation)  
PI US 6423312 B2 20020723  
AI US 1998-140888 19980827 (9)  
RLI Continuation-in-part of Ser. No. US 1998-46475, filed on 25 Mar 1998, now patented, Pat. No. US 6153187 Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, now patented, Pat. No. US 5968822  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Prout, Rebecca E.  
LREP G.E. Ehrlich Ltd.  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Figure(s); 7 Drawing Page(s)  
LN.CNT 1120

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 83 OF 86 USPAT2 on STN  
AN 2002:85159 USPAT2  
TI Treatment of prophylaxis of diseases caused by pilus-forming bacteria  
IN Hultgren, Scott, Ballwin, MO, United States  
Kuehn, Meta, Berkeley, CA, United States  
Xu, Zheng, Blue Bell, PA, United States  
Ogg, Derek, Uppsala, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, United States  
Kihlberg, Jan, Dalby, SWEDEN  
PA Washington University, St. Louis, MO, United States (U.S. corporation)  
SIGA Pharmaceuticals, Inc., New York, NY, United States (U.S. corporation)  
PI US 6596504 B2 20030722  
AI US 2001-799540 20010307 (9)  
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Swartz, Rodney P  
LREP Burns, Doane, Swecker & Mathis, L.L.P.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 35 Drawing Figure(s); 24 Drawing Page(s)  
LN.CNT 5179

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 84 OF 86 USPAT2 on STN  
AN 2002:60940 USPAT2  
TI Treatment or prophylaxis of diseases caused by pilus-forming  
bacteria  
IN Hultgren, Scott, Ballwin, MO, United States  
Kuehn, Meta, Berkeley, CA, United States  
Xu, Zheng, Blue Bell, PA, United States  
Ogg, Derek, Uppsala, SWEDEN  
Harris, Mark, Uppsala, SWEDEN  
Lepisto, Matti, Lund, SWEDEN  
Jones, Charles Hal, Saint Louis, MO, United States  
Kihlberg, Jan, Dalby, SWEDEN  
PA Washington University, St. Louis, MO, United States (U.S. corporation)  
Siga Pharmaceuticals, Inc., Corvallis, OR, United States (U.S.  
corporation)  
PI US 6548265 B2 20030415  
AI US 2001-799576 20010307 (9)  
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, now patented,  
Pat. No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 18  
Nov 1994 Continuation-in-part of Ser. No. US 1993-154035, filed on 18  
Nov 1993, now abandoned  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Swartz, Rodney P  
LREP Burns, Doane, Swecker & Mathis, L.L.P.  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 35 Drawing Figure(s); 25 Drawing Page(s)  
LN.CNT 5270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for the treatment and/or prophylaxis of diseases  
caused by tissue-adhering bacteria are disclosed. By interacting with  
periplasmic molecular chaperones it is achieved that the assembly of  
pili is prevented or inhibited and thereby the infectivity of the  
bacteria is diminished. Also disclosed are methods for screening for  
drugs as well as methods for the de novo design of such drugs, methods  
which rely on novel computer drug modelling methods involving an  
approximative calculation of binding free energy between macromolecules.  
Finally, novel pyranosides which are believed to be capable of  
interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 85 OF 86 USPAT2 on STN  
AN 2001:170867 USPAT2  
TI Colorimetric glycopolythiophene biosensors  
IN Charych, Deborah J., Albony, CA, United States  
Baek, Myung-Gi, Ottawa, CANADA  
PA Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)  
PI US 6660484 B2 20031209  
AI US 2000-734410 20001211 (9)  
RLI Continuation-in-part of Ser. No. US 1999-461509, filed on 14 Dec 1999,  
now patented, Pat. No. US 6395561 Division of Ser. No. US 1996-592724,  
filed on 26 Jan 1996, now patented, Pat. No. US 6001556, issued on 14  
Dec 1999 Continuation-in-part of Ser. No. US 1993-159927, filed on 30  
Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1992-976697,  
filed on 13 Nov 1992, now abandoned Continuation-in-part of Ser. No. US  
2000-500295, filed on 8 Feb 2000 Division of Ser. No. US 1997-920501,  
filed on 29 Aug 1997, now patented, Pat. No. US 6022748, issued on 8 Feb  
2000 Continuation-in-part of Ser. No. US 1998-103344, filed on 23 Jun  
1998 Continuation-in-part of Ser. No. US 1996-609312, filed on 1 Mar  
1996, now patented, Pat. No. US 6183772 Continuation-in-part of Ser. No.  
US 1995-389475, filed on 13 Feb 1995, now abandoned Continuation-in-part  
of Ser. No. US 1994-289384, filed on 11 Aug 1994, now abandoned  
Continuation-in-part of Ser. No. US 1994-328237, filed on 24 Oct 1994,  
now abandoned Continuation-in-part of Ser. No. US 1997-944323, filed on

6 Oct 1997, now patented, Pat. No. US 6180135 Division of Ser. No. US 389475 Continuation-in-part of Ser. No. US 289384 Continuation-in-part of Ser. No. US 328237 Continuation-in-part of Ser. No. US 1998-23898, filed on 13 Feb 1998 Continuation-in-part of Ser. No. US 1998-33557, filed on 2 Mar 1998 Continuation-in-part of Ser. No. US 1999-337973, filed on 21 Jun 1999, now patented, Pat. No. US 6306598

PRAI US 1999-170190P 19991210 (60)  
US 1998-90266P 19980622 (60)  
US 1997-50496P 19970623 (60)  
US 1997-38383P 19970214 (60)  
US 1997-39749P 19970303 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Housel, James; Assistant Examiner: Brown, Stacy S.

LREP Hedlen & Carroll, LLP

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the direct detection of analytes using observable spectral changes in biopolymeric systems. In particular, the present invention allows for the direct colorimetric detection of analytes using color changes that occur in glycopolythiophene polymer systems in response to selective binding of analytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 86 OF 86 WPINDEX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2004-570523 [55] WPINDEX

DNC C2004-208289

TI Use of D-mannose for maintenance of urinary tract health in the face of infection e.g. E. Coli infection.

DC B03 B04

IN ONEAL, J; WHITE, G

PA (ONEA-I) ONEAL J; (WHIT-I) WHITE G

CYC 1

PI US 2004147459 A1 20040729 (200455)\* 6

ADT US 2004147459 A1 Provisional US 2002-420696P 20021023, US 2003-691423 20031022

PRAI US 2002-420696P 20021023; US 2003-691423 20031022

AN 2004-570523 [55] WPINDEX

AB US2004147459 A UPAB: 20040826

NOVELTY - Maintenance of urinary tract health in the face of infection involves administering a dosage of 1 - 2 teaspoons of D-mannose three times a day with meals for 1 - 2 weeks or until the symptoms subside.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition comprising a therapeutic dosage of D-mannose and a therapeutic dosage of at least one of an extract of Crataeva nurvala, willow bark or pollen extract simultaneously with D-mannose.

ACTIVITY - Uropathic; Antimicrobial.

MECHANISM OF ACTION - E. coli urethral epithelial cell attachment inhibitor.

USE - For maintaining urinary tract health in the face of infection; in combination with a capsule containing herbs that affect the urinary tract; and for dealing with a urinary tract infection (all claimed). The urinary tract infection include E. coli infection.

ADVANTAGE - The use of D-mannose in the maintenance of urinary tract health in the face of infection and in the treatment of urinary tract infection preferentially provides attachment of E. coli fimbriae to the administered D-mannose present in the urine, rather than attachment to D-mannose in the epithelial cells of the urinary tract. This results in the E. coli bacteria surrounded by the molecules of D-mannose and promotes their natural elimination by

mechanical and not pharmacological action. The few remaining bacteria can then be better handled by the body's natural defenses, the white blood cells. Mannose can not be broken down in the body, and thus is safe for diabetics, pregnant women and the elderly, and is virtually free from the risk of overdose. The method does not involve the use of antibiotics and hence avoids the side effects and resistant strain development associated with them. The administration regimen provides a quantity of mannose sufficient to remove a majority of E/ coli in the urinary tract, while improving the ease of use and compliance. The dosages are effective in doctor-run trials.

Dwg.0/3

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

295.45

295.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.00

-3.00

FILE 'CAPLUS' ENTERED AT 09:36:58 ON 30 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2006 VOL 144 ISS 6

FILE LAST UPDATED: 29 Jan 2006 (20060129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s Oneal Joseph/AU

L8 1 ONEAL JOSEPH/AU

=> dis l8 bib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:612489 CAPLUS

DN 141:117126

TI Method and composition for maintaining urinary tract health in the face of infections

IN Oneal, Joseph; White, Gary

PA USA

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI	US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be

of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

=> s White Gary/AU

L9 8 WHITE GARY/AU

=> dis l9 1-8 bib abs

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:612489 CAPLUS

DN 141:117126

TI Method and composition for maintaining urinary tract health in the face of infections

IN Oneal, Joseph; White, Gary

PA USA

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI	US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:493491 CAPLUS

DN 141:39547

TI Laminated siding panels having preselected colors

IN Regelski, Joe R.; Levendusky, Thomas L.; White, Gary

PA USA

SO U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004115398	A1	20040617	US 2002-318427	20021213
	US 2005003154	A1	20050106	US 2004-817604	20040402
PRAI	US 2002-318427	A2	20021213		

AB A process for making laminated plastic panels suitable for use on buildings and having a preselected color, comprises the steps of: forming a plastic sheet at an elevated temperature, the formed sheet having an exterior surface portion; overlaying the exterior surface portion of the formed sheet with a coloring sheet having a preselected color and comprising a polymeric binder and pigment particles, said binder comprising a plastisol; and laminating the coloring sheet to the formed sheet by means of a roll continuously contacting the coloring sheet, said formed sheet maintaining a sufficient temperature while pressure is applied to the roll to bond said coloring sheet to said formed sheet, thereby to produce a laminated plastic panel having a preselected color. The coloring sheet

preferably comprises a vinyl resin plastisol and pigment particles. Both the formed sheet and the vinyl resin in the plastisol preferably comprise polyvinyl chloride (PVC). Use of the coloring sheet enables color changes to be accomplished quickly and inexpensively so that manufacturers are able to maintain smaller inventories of the finished product while still satisfying customer needs.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:8747 CAPLUS

TI Episodic blockade of cranial nerve VIII provokes asymmetric changes in lobule X of the rat

AU Saxon, Dale W.; White, Gary

CS Evansville Center for Medical Education, Department of Anatomy and Cell Biology, Indiana University School of Medicine, Evansville, IN, 47712, USA

SO Brain Research (2004), 997(2), 165-175

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

AB Although debilitating syndromes like Meniere's disease are in part characterized by recurrent or episodic vestibular disturbance the study of episodic vestibular disruption has only recently been possible with the introduction of a new model utilizing tetrodotoxin (TTX). In the present study, serial unilateral transtympanic administration of TTX produced behavioral symptoms indicative of transient vestibular disruption and novel patterns of Fos activity in the brainstem and cerebellum. Following two or three serial injections of TTX and a final survival time of 2 h, Fos immunocytochem. revealed a distinct pattern of labeling in the brainstem that differed temporally from that observed following a single unilateral TTX injection. Specifically there was protracted expression of Fos in the  $\beta$  subdivision of the inferior olive (IO) on the side ipsilateral to TTX treatment. In the cerebellum, the hallmark of episodic vestibular blockade was an asym. pattern of Fos labeling that involved all three layers of the cortex. In particular, there was prominent Fos labeling of Purkinje cells in the contra-TTX half of lobule X. In view of the fact that Fos labeling is not found in Purkinje cells following a single transient event or following peripheral vestibular ablation, it is suggested that Fos expression in Purkinje cells is a unique feature of episodic vestibular disruption and may represent a novel plastic response by a select population of Purkinje cells to episodic functional deafferentation.

RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:526796 CAPLUS

DN 139:288865

TI Novel Kaposi's sarcoma-associated herpesvirus homolog in baboons

AU Whitby, Denise; Stossel, Andrea; Gamache, Christine; Papin, James; Bosch, Marnix; Smith, Anne; Kedes, Dean H.; White, Gary; Kennedy, Ronald; Dittmer, Dirk P.

CS Viral Epidemiology Section, AIDS Vaccine Program, National Cancer Institute-Frederick, SAIC-Frederick, Frederick, MD, 21702, USA

SO Journal of Virology (2003), 77(14), 8159-8165

CODEN: JOVIAM; ISSN: 0022-538X

PB American Society for Microbiology

DT Journal

LA English

AB Kaposi's sarcoma (KS) and lymphoproliferative diseases induced by KS-associated herpesvirus (KSHV/human herpesvirus 8) cause substantial morbidity and mortality in human immunodeficiency virus-infected individuals. To understand KSHV biol. it is useful to investigate closely related rhadinoviruses naturally occurring in nonhuman primates. Here we report evidence for a novel KSHV homolog in captive baboon species (*Papio anubis* and other). Using degenerate PCR we identified a novel rhadinovirus, PapRV2, that has substantial sequence identity to 2 essential KSHV genes, the viral polymerase and thymidylate synthase. A subset of animals exhibited detectable PapRV2 viral load in peripheral blood mononuclear cells. Extensive serol. anal. of nearly 200 animals in

the colony demonstrated that the majority carried cross-reacting antibodies that recognize KSHV or macaque rhadinovirus antigens. Seroreactivity increased with age, similar to the age-specific prevalence of KSHV in the human population. This establishes baboons as a novel resource to investigate rhadinovirus biol., which can be developed into an animal model system for KSHV-associated human diseases, vaccine development, and therapy evaluation.

RE.CNT 58      THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9      ANSWER 5 OF 8    CAPLUS    COPYRIGHT 2006 ACS on STN

AN      2000:855405    CAPLUS

DN      134:159973

TI      Simian foamy virus infections in a baboon breeding colony

AU      Blewett, Earl L.; Black, Darla H.; Lerche, Nicholas W.; White, Gary; Eberle, R.

CS      College of Osteopathic Medicine, Oklahoma State University, Tulsa, OK, 74107, USA

SO      Virology (2000), 278(1), 183-193

      CODEN: VIRLAX; ISSN: 0042-6822

PB      Academic Press

DT      Journal

LA      English

AB      The prevalence, transmission, and variation of simian foamy viruses (SFVs) in baboons was investigated. Over 95% of adult baboons in the breeding colony as well as recently imported adult animals had high titers of anti-SFV serum IgG. Maternal antibody was detectable in infants' serum up to 6 mo of age. Approx. 30% of infants in breeding harems experienced SFV infections by 1 yr of age. Shedding of SFV in oral secretions was common, with 13% of samples from normal adult animals and 35% from immunosuppressed animals containing infectious SFV. SFV was isolated from three baboon subspecies (olive, yellow, and chacma baboons) and sequences from both the pol and the LTR regions of the provirus were amplified by PCR and sequenced. Phylogenetic anal. indicated that all baboon isolates formed a single lineage distinct from SFVs of other African monkey species. Within the baboon SFV lineage, two distinct clades were apparent, which consisted of isolates from yellow and olive baboons and isolates from chacma baboons. Competition ELISAs indicated that, while SFV isolates of these two groups were very closely related, antigenic differences do exist between them. SFV isolates from a drill and a mandrill were distinct from baboon SFV isolates, both genetically and antigenically. (c) 2000 Academic Press.

RE.CNT 19      THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9      ANSWER 6 OF 8    CAPLUS    COPYRIGHT 2006 ACS on STN

AN      1998:813451    CAPLUS

DN      130:174798

TI      Optical characterization of organic nonlinear optical crystals irradiated with MeV protons, an electron paramagnetic resonance study

AU      Darwish, A. M.; Thompson, Tommy; Williams, Alton; Bhat, Kamala; Thompson, James; Chelette, Kelly; LaFitte, Shane; Hyde, Wayne; White, Gary; Glass, Gary A.; Wang, Yongqiang

CS      Center for nonlinear optics and materials, Physics Department, Alabama A&M University, Normal, AL, 35867, USA

SO      Proceedings of SPIE-The International Society for Optical Engineering (1998), 3470(Photorefractive Fiber and Crystal Devices: Materials, Optical Properties, and Applications IV), 152-161

      CODEN: PSISDG; ISSN: 0277-786X

PB      SPIE-The International Society for Optical Engineering

DT      Journal

LA      English

AB      In processes of obtaining a new NLO materials, modifying and enhancing the existing materials, various aromatic compds. were synthesized with the intent of comparing their nonlinear optical properties. Different techniques were used to characterize the proton-irradiated N-isobutyl-4-methyl-6-nitro-2-quinolinamine sample. From the ESR measurements: the spin concentration seemed to increase significantly when the proton beam increased from 0 to 2.2 MeV and then the spin concentration starts decreasing up to 3 MeV. The EPR signal



for N- iso-Bu was singlet up to 1.8 MeV then split into doublet around 2 MeV, then triplet around 2.2 and then returned again to a weak singlet around 3 MeV. Using LB film for these samples, the SH is maximum for the 2.2 MeV-irradiated-sample. FTIR anal. also shows a dramatic increase in transmission in different bands of the spectra. Due to higher energy proton irradiation, a high significant improvement in the nonlinear characteristics of the sample was observed. A theor. interpretation for the effect of the proton irradiation enhancement of the nonlinearity of these will be presented as well.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1981:578370 CAPLUS  
DN 95:178370  
TI Narrow-band linearly scannable infrared lasing between 1.09 and 1.12  $\mu\text{m}$   
in the dye DNDTPC perchlorate  
AU White, Gary; Pruett, J. Gary  
CS Dep. Chem., Univ. Pennsylvania, Philadelphia, PA, 19104, USA  
SO Optics Letters (1981), 6(10), 473-4  
CODEN: OPLEDP; ISSN: 0146-9592  
DT Journal  
LA English  
AB A grazing-incidence grating-tuned oscillator followed by 2 amplifier stage  
was used to generate 0.2-cm-1 bandwidth scannable IR radiation between  
1.09 and 1.12  $\mu\text{m}$  in 3,3'-diethyl-9,11,15,17-dineopentylene-(6,7,7',7'-  
dibenzo)thiapentacarbocyanine perchlorate (DNDTPC). When the radiation  
was pumped with 400-mJ 10-ns pulses from a Nd:YAG laser, the output-pulse  
energy was .apprx.20 mJ at the peak of the tuning curve.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1978:176465 CAPLUS  
DN 88:176465  
TI Health hazard evaluation determination report number 76-94-406,  
Westinghouse Electric Corporation, Large Power Transformer Division,  
Muncie, Indiana  
AU Hervin, Raymond L.; Smith, Alexander Blair; White, Gary  
CS Natl. Inst. Occup. Saf. Health, Cincinnati, OH, USA  
SO U. S. NTIS, PB Rep. (1977), PB-273722, 19 pp. Avail.: NTIS  
From: Gov. Rep. Announce. Index (U. S.) 1978, 78(3), 65  
CODEN: XPBRCA; ISSN: 0099-8583  
DT Report  
LA English  
AB Environmental air sampling and medical evaluation concluded that  
employees' exposure to airborne total nuisance particulates, oil mists,  
and organic vapors did not pose a health hazard at the concentration measured. The  
majority of the 20 affected employees gave a history of apparent  
dermatitis with the oil which is adherent to surfaces of the transformer  
as it is assembled. The contention that the transformer oil may contain  
additives which could be responsible for the apparent toxic manifestations  
of the oil was not borne out by the investigation. Recommendations are  
made to alleviate dermatitis problems caused by direct contact with the  
oil.

=> dis hist

(FILE 'HOME' ENTERED AT 09:23:37 ON 30 JAN 2006)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT,  
JICST-EPLUS, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH,  
USPATFULL, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, MEDLINE, BIOSIS,  
EMBASE' ENTERED AT 09:24:02 ON 30 JAN 2006

L1 118295 S URINARY(A) TRACT(A) INFECT?  
L2 42971 S L1 AND TREAT?  
L3 142 S L2 AND D-MANNOSE  
L4 5 S L3 AND (CRATAEVA OR WILLOW OR POLLEN)  
L5 7 S L3 AND (CRATAVIN OR SALICIN)  
L6 86 S L3 AND (CAPSULE OR POWDER)

L7 1 S L3 AND LUPEOL

FILE 'CAPLUS' ENTERED AT 09:36:58 ON 30 JAN 2006

L8 1 S ONEAL JOSEPH/AU

L9 8 S WHITE GARY/AU